<!DOCTYPE html>
<html>
<head>

      <meta http-equiv="Content-Type" content="text/html; charset=utf-8">

        <script> var url = encodeURIComponent('https://www.webmd.com/dna/the-turning-point/dvt-pe');</script>

        <script> var body_html = '<body> <header ></header> <div ><div ><div > <div > <div > <h1 ><a >THE TURNING POINT</a></h1> <div > <ul> <li> <a > AFIB </a> </li> <li> <a > DVT/PE </a> </li> <li> <a > CAD </a> </li> </ul> </div> </div> <div > <div > <div > <div > <p >Finding resilience after recurring events</p> <div > <p>JOE</p> <p>Age 68</p> <p>Diagnosed with DVT/PE in 2012</p> </div> </div> </div> <div > <div > <p >Joe is a 68-year-old retiree who lives in Hawaii. He spends his time going to the beach, fishing, cycling, and gardening with his wife. By the looks of it, you would never know that Joe has suffered from recurring pulmonary embolisms (PE). His first one occurred in the middle of the night after a flight from Hawaii to Arizona. "I woke up and couldn't take a full breath, so I went to the emergency room," Joe said. There, the doctor asked Joe if he was having trouble with his left leg and if he had recently been on an airplane for an extended period. The answer to both was yes, and after "a battery of tests," Joe's doctors determined he had a PE. "I was surprised and very overwhelmed," Joe said. "There had been a knot in my left leg. I did the normal thing. Massage the muscle. Soak it in hot water. I did all those kind of things…and nothing seemed to work. [Had] I known about pulmonary embolisms, I probably would've got up and walked around, drank more water, all the things that I do now [while traveling]." Joe was prescribed warfarin to treat and help reduce the risk of another PE.</p> </div> </div> </div> <div > What is DVT/PE? <p>A PE occurs when a blood clot called a deep vein thrombosis (DVT) forms and travels to your lungs. DVT forms in a vein deep inside your body, such as in the legs. DVT is the third most common vascular diagnosis behind heart attack and stroke. It affects between 300,000 and 600,000 people in the US every year.</p> <div > <div > <div > <p>An estimated 60,000-100,000 Americans DIE OF DVT/PE every year.</p> </div> <div > <p>Up to 12% of future DVT or PE blood clots RESULT IN A FATAL PE. </p> </div> </div> </div> <div > Risk Factors <p>Certain people are at higher risk for DVT/PE events: those who smoke, are over the age of 60, overweight, pregnant, or have a family history of blood clots. Slow blood flow due to immobility during extended travel, having a recent injury or surgery, and taking hormone medications are also risk factors. Joe met several of these criteria and experienced some telltale symptoms, which helped his doctors diagnose him. "Unexplained acute cough, especially if associated with blood, new and sudden shortness of breath, low oxygen levels, and, in extreme situations, cramping of the calf muscle, chest pain, passing out, or vision changes" are signs to watch out for, according to Dr. Kamran Boka, a pulmonary attending physician.</p> </div> <div > <div ><h2>FAMILIARIZE YOURSELF WITH THE RISK FACTORS</h2></div> <div > <div > <h3>SLOW BLOOD FLOW</h3> <ul> <li>During extended travel</li> <li>After surgery</li> <li>During illness</li> </ul> </div> </div> <div > <div > <h3>CERTAIN MEDICATIONS</h3> <ul> <li>Oral contraceptives</li> <li>Hormone therapy</li> <li>Cancer treatments</li> </ul> </div> </div> <div > <div > <h3>CERTAIN CHARACTERISTICS</h3> <ul> <li>Being overweight</li> <li>Smoking</li> <li>Being over 60 years of age</li> </ul> </div> </div> <div > <div > <h3>INJURY TO A DEEP VEIN</h3> <ul> <li>Surgery</li> <li>Trauma</li> </ul> </div> </div> <div > <div > <h3>MEDICAL HISTORY</h3> <ul> <li>Blood clotting disorders</li> <li>Family history of blood clots</li> </ul> </div> </div> <div > <div > <p>If you've already had a DVT or PE, YOUR RISK FOR ANOTHER INCREASES OVER TIME.</p> </div> </div> </div> </div> <div > <div > <h3 >Joe's Turning Point</h3> </div> <div > <p>Unfortunately, Joe's first PE was not his last. "The disheartening thing is once you have one, you're more susceptible to have another one," Joe said. A year later, he was setting up chairs for an event when he started feeling the same sensation in his chest that he felt the night of his first PE. Immediately, Joe knew what was happening and went to the hospital, where he was diagnosed with another PE. There were no obvious causes for this event, so Joe continued taking warfarin, the medication initially prescribed for his condition, until he had yet another PE blood clot event the next year. That's when he and his doctors decided to revisit his treatment plan.</p> <p>There are different types of blood thinners that treat DVT/PE. Anticoagulants help prevent or reduce blood clotting, and antiplatelet drugs help keep platelets (a type of blood cell) from sticking together and forming a clot.</p> <div > <p >“We want to reduce the stickiness of the blood and prevent existing clots from getting bigger. Anticoagulation blocks clotting and reduces that from happening."</p> <p >Dr. Kamran Boka</p> </div> <p>Joe's doctors recommended he start taking XARELTO<sup>®</sup>, a blood thinner prescribed to treat and reduce the risk of DVT/PE blood clots from happening again. "I was happy to get it and happy to get on with my life," Joe said. "Getting back [to your life] after you've had a PE is the place every patient wants to be."</p> </div> </div> <div > <div > <div > <div > <div > <h2>How do I know if I'm at risk for a DVT or PE event?</h2> <p>Deep vein thrombosis (DVT) and pulmonary embolism (PE) blood clot events can be unexpected and scary, and there are several risk factors known to increase the possibility of a DVT/PE event.</p> </div> </div> <div > <div > <h2>What are the symptoms of DVT?</h2> <p>A common symptom is swelling in the affected limb, which is usually in the leg.</p> <p>You might also feel cramping that turns into pain, skin that is warm to the touch, or see red or discolored skin.</p> </div> </div> <div > <div > <h2>What are the symptoms of PE?</h2> <p>Symptoms include sudden or unexplained shortness of breath, rapid breathing, chest pain under the rib cage that may worsen with deep breaths, feeling lightheaded, or coughing up blood. </p> </div> </div> <div > <div > <h2>What are the consequences?</h2> <p>PE is actually a complication of DVT and occurs when the DVT blood clot travels to the lungs. This blocks blood flow to the lungs, which can be life-threatening.</p> </div> </div> <div > <div > <h2>What do I do if I have a DVT or PE event?</h2> <p>If you experience any symptoms of DVT or PE, seek medical attention immediately. This is because a DVT can become a PE, and PEs are often confused with other conditions like pneumonia.</p> <p>It can be difficult for you to determine how serious the situation is. Blood clots can be life-threatening, so it's important to notify your doctor right away. </p> </div> </div> <div > <div > <h2>How can I help prevent a DVT or PE event?</h2> <p>There are simple things you can do to reduce the risk of DVT/PE: avoiding sitting still for long periods, maintaining a healthy weight, staying active, and quitting smoking. </p> <p>However, if you've already had an event, your risk of having another increases over time. In this case, taking blood thinners may help in prevention.</p> </div> </div> <div > <div > <h2>What treatments are available for DVT/PE?</h2> <p>Blood thinners are used to treat DVT/PE blood clots by helping to prevent blood clots from growing larger and helping stop other clots from forming.</p> <p>XARELTO<sup>®</sup> is a blood thinner proven to treat and reduce the risk of DVT/PE blood clots from happening again. In clinical studies, almost 98% of people taking XARELTO<sup>®</sup> did not experience another DVT or PE.*</p> <p>XARELTO<sup>®</sup> has no known dietary restrictions and doesn't require regular blood monitoring.</p> <p>*patients were followed for an average of 208 days.</p> </div> </div> <div > <div > <h2>I completed treatment for my initial DVT/PE, am I still at risk? </h2> <p>After completing treatment for an initial DVT or PE, some people remain at risk for another event and may need to continue taking a blood thinner to help reduce their underlying risk. Some may take aspirin to help reduce their risk.</p> </div> </div> <div > <div > <h2>Is aspirin enough to help reduce my risk over time?</h2> <p>Aspirin may not be enough. XARELTO<sup>®</sup> is the only blood thinner that has been studied against aspirin and was proven to significantly reduce the risk of recurrent DVT/PE in people who have completed six months of treatment for an initial event.</p> <p>In a clinical trial, people taking XARELTO<sup>®</sup> 10 mg were 3 times less likely to have another DVT or PE compared to people taking aspirin alone.</p> </div> </div> <div > <div > <h2>What else can I do to help reduce my risk of a future DVT/PE blood clot?</h2> <p>Be sure to do your research, maintain healthy habits, know the symptoms, keep in touch with your healthcare team and be sure to take your medication as prescribed.</p> </div> </div> </div> </div> <div > <div > <div ><p >Blood thinners are used to treat DVT/PE by PREVENTING CLOTS FROM GROWING AND NEW ONES FROM FORMING.</p></div> </div> <div > <div ><p >Blood thinners may continue to be taken to reduce the risk of future blood clots, even after completion of initial treatment. Work with your doctor to determine your need based on your risk factors.</p></div> </div> </div> <div > <div > <div ><h3 >AFTER 5 YEARS</h3></div> </div> <div > <div ><h3 >AFTER 10 YEARS</h3></div> </div> </div> <p>After switching to XARELTO<sup>®</sup> from warfarin, Joe noticed some immediate advantages. "[Warfarin] was problematic [for me] because of the [dietary] restrictions … And that was something you really had to watch out for," Joe said. "[You also] had to have your blood [tested regularly]. That's something you don't have to do with XARELTO<sup>®</sup>."</p> <p>People taking XARELTO<sup>®</sup> will take a higher dose during the first three weeks after a DVT or PE blood clot diagnosis, when the risk of having another one is the highest. </p> <p>If you've had a DVT or PE, your risk of having another one increases over time, particularly once you complete treatment and no longer take a prescription blood thinner. In addition, future events can be more serious—even life-threatening. Up to 12% of future DVT or PE blood clots result in a fatal PE. XARELTO<sup>®</sup> was the only blood thinner studied vs aspirin that was proven to significantly reduce the risk of recurrent DVT/PE in people who had already completed six months of treatment for an initial event. In a clinical trial, people taking XARELTO<sup>®</sup> 10 mg were 3 times less likely to have another DVT or PE compared to people taking aspirin alone.</p> <div > Maintaining a Positive Outlook <p>Beyond taking his medication, Joe takes steps to stay healthy by eating right and keeping his weight down. "I work out a lot. I cycle. I do as much hiking and walking as I can," Joe said. He also leans on his wife for additional support. "My wife has been very supportive. We support each other in our health. She's more athletic than me, so that keeps me pretty active—trying to keep up with her." And he is committed to doing what he needs to do to stay healthy. "I just take [my medicine], do what my doctors say, try to stay as healthy as I can and live my life and be happy."</p> <p>If you have had a DVT or PE event, you know how scary it can be; however, it is manageable with treatment. That's why it's important to listen to your body like Joe did and know any symptoms that might indicate a blood clot. Remember, DVT/PE events are often unexpected, and your risk of having another increases over time. Talk to your doctor about treatment options and how to best help lower your risk. </p> </div> <div > <div ><p >In clinical trials, almost 98% of people taking XARELTO<sup>®</sup> DID NOT HAVE ANOTHER DVT OR PE.*</p> <p >*Patients were followed for an average length of treatment of 208 days. </p></div> </div> <div > <div ><p>YOUR DOCTOR IS ALWAYS YOUR BEST RESOURCE. He or she knows your situation best and can help you determine a treatment plan.</p></div> </div> </div> <div > <div > <h1>Find out more about how to help reduce your risk of another DVT or PE with XARELTO<sup>®</sup></h1> Learn More </div> </div> </div> </div> </div> </div><div ><div > <div > <div > <div > <div > <div > <div > WHAT IS XARELTO<sup>®</sup> (rivaroxaban)?</div> <div > <p>XARELTO<sup>®</sup> is a prescription medicine used to:</p> <ul> <li> reduce the risk of stroke and blood clots in people who have a medical condition called atrial fibrillation that is not caused by a heart valve problem. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to the formation of blood clots, which can travel to the brain, causing a stroke, or to other parts of the body </li> <li> treat blood clots in the veins of your legs (deep vein thrombosis or DVT) or lungs (pulmonary embolism or PE) </li> <li> reduce the risk of blood clots happening again in people who continue to be at risk for DVT or PE after receiving treatment for blood clots for at least 6 months </li> </ul> <p>XARELTO<sup>®</sup> is used with low dose aspirin to:</p> <ul> <li> reduce the risk of serious heart problems, heart attack and stroke in people with coronary artery disease (a condition where the blood supply to the heart is reduced or blocked) or peripheral artery disease (a condition where the blood flow to the legs is reduced) </li> </ul> <p>It is not known if XARELTO<sup>®</sup> is safe and effective in children.</p> </div> </div> <div > <div >WHAT IS XARELTO<sup>®</sup> (rivaroxaban)?</div> <div > <p>XARELTO<sup>®</sup> is a prescription medicine used to:</p> <ul> <li>reduce the risk of stroke and blood clots in people who have a medical condition called atrial fibrillation that is not caused by a heart valve problem. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to the formation of blood clots, which can travel to the brain, causing a stroke, or to other parts of the body</li> </ul> <p>It is not known if XARELTO<sup>®</sup> is safe and effective in children.</p> </div> </div> <div > <div >WHAT IS XARELTO<sup>®</sup> (rivaroxaban)?</div> <div > <p>XARELTO<sup>®</sup> is a prescription medicine used to:</p> <ul> <li>treat blood clots in the veins of your legs (deep vein thrombosis or DVT) or lungs (pulmonary embolism or PE)</li> <li>reduce the risk of blood clots happening again in people who continue to be at risk for DVT or PE after receiving treatment for blood clots for at least 6 months</li> </ul> <p>It is not known if XARELTO<sup>®</sup> is safe and effective in children.</p> </div> </div> <div > <div >WHAT IS XARELTO<sup>®</sup> (rivaroxaban)?</div> <div > <p>XARELTO<sup>®</sup> is a prescription medicine used with low dose aspirin to:</p> <ul> <li>reduce the risk of serious heart problems, heart attack and stroke in people with coronary artery disease (a condition where the blood supply to the heart is reduced or blocked) or peripheral artery disease (a condition where the blood flow to the legs is reduced) </li> </ul> <p>It is not known if XARELTO<sup>®</sup> is safe and effective in children.</p> </div> </div> </div> <div > <h3 >IMPORTANT SAFETY INFORMATION</h3> <p >WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT XARELTO<sup>®</sup>?</p> <p> XARELTO<sup>®</sup> may cause serious side effects, including: </p> <ul > <li> Increased risk of blood clots if you stop taking XARELTO<sup>®</sup>. People with atrial fibrillation (an irregular heart beat) that is not caused by a heart valve problem (nonvalvular) are at an increased risk of forming a blood clot in the heart, which can travel to the brain, causing a stroke, or to other parts of the body. XARELTO<sup>®</sup> lowers your chance of having a stroke by helping to prevent clots from forming. If you stop taking XARELTO<sup>®</sup>, you may have increased risk of forming a clot in your blood. </li> <li > Do not stop taking XARELTO<sup>®</sup> without talking to the doctor who prescribes it for you. Stopping XARELTO<sup>®</sup> increases your risk of having a stroke. If you have to stop taking XARELTO<sup>®</sup>, your doctor may prescribe another blood thinner medicine to prevent a blood clot from forming. </li> <li> Increased risk of bleeding. XARELTO<sup>®</sup> can cause bleeding which can be serious, and may lead to death. This is because XARELTO<sup>®</sup> is a blood thinner medicine (anticoagulant) that lowers blood clotting. During treatment with XARELTO<sup>®</sup> you are likely to bruise more easily, and it may take longer for bleeding to stop. You may be at higher risk of bleeding if you take XARELTO<sup>®</sup> and have certain other medical problems. </li> </ul> <p > You may have a higher risk of bleeding if you take XARELTO<sup>®</sup> and take other medicines that increase your risk of bleeding, including: </p> <ul > <li>Aspirin or aspirin-containing products</li> <li>Long-term (chronic) use of non-steroidal anti-inflammatory drugs (NSAIDs)</li> <li>Warfarin sodium (Coumadin<sup>®</sup>, Jantoven<sup>®</sup>)</li> <li>Any medicine that contains heparin</li> <li>Clopidogrel (Plavix<sup>®</sup>)</li> <li>Selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs)</li> <li>Other medicines to prevent or treat blood clots</li> </ul> <p > Tell your doctor if you take any of these medicines. Ask your doctor or pharmacist if you are not sure if your medicine is one listed above. </p> <p > Call your doctor or get medical help right away if you develop any of these signs or symptoms of bleeding: </p> <ul > <li>Unexpected bleeding or bleeding that lasts a long time, such as:</li> </ul> <ul > <li>Nosebleeds that happen often</li> <li>Unusual bleeding from gums</li> <li>Menstrual bleeding that is heavier than normal, or vaginal bleeding</li> </ul> <ul > <li>Bleeding that is severe or you cannot control</li> <li>Red, pink, or brown urine</li> <li>Bright red or black stools (looks like tar)</li> <li>Cough up blood or blood clots</li> <li>Vomit blood or your vomit looks like "coffee grounds"</li> <li>Headaches, feeling dizzy or weak</li> <li >Pain, swelling, or new drainage at wound sites</li> </ul> <li > Spinal or epidural blood clots (hematoma). People who take a blood thinner medicine (anticoagulant) like XARELTO<sup>®</sup>, and have medicine injected into their spinal and epidural area, or have a spinal puncture, have a risk of forming a blood clot that can cause long-term or permanent loss of the ability to move (paralysis). Your risk of developing a spinal or epidural blood clot is higher if: <ul > <li> A thin tube called an epidural catheter is placed in your back to give you certain medicine </li> <li> You take NSAIDs or a medicine to prevent blood from clotting </li> <li> You have a history of difficult or repeated epidural or spinal punctures </li> <li> You have a history of problems with your spine or have had surgery on your spine </li> </ul> </li> <p > If you take XARELTO<sup>®</sup> and receive spinal anesthesia or have a spinal puncture, your doctor should watch you closely for symptoms of spinal or epidural blood clots. Tell your doctor right away if you have back pain, tingling, numbness, muscle weakness (especially in your legs and feet), or loss of control of the bowels or bladder (incontinence). </p> <p> XARELTO<sup>®</sup> is not for use in people with artificial heart valves. </p> <p> XARELTO<sup>®</sup> is not for use in people with antiphospholipid syndrome (APS), especially with positive triple antibody testing. </p> <p > ​​Do not take XARELTO<sup>®</sup> if you: </p> <ul > <li> Currently have certain types of abnormal bleeding. Talk to your doctor before taking XARELTO<sup>®</sup> if you currently have unusual bleeding. </li> <li> Are allergic to rivaroxaban or any of the ingredients of XARELTO<sup>®</sup>. </li> </ul> <p > ​​Before taking XARELTO<sup>®</sup>, tell your doctor about all your medical conditions, including if you: </p> <ul > <li> Have ever had bleeding problems </li> <li> Have liver or kidney problems </li> <li> Have antiphospholipid syndrome (APS) </li> <li> Are pregnant or plan to become pregnant. It is not known if XARELTO<sup>®</sup> will harm your unborn baby. <ul> <li> Tell your doctor right away if you become pregnant during treatment with XARELTO<sup>®</sup>. Taking XARELTO<sup>®</sup> while you are pregnant may increase the risk of bleeding in you or in your unborn baby. </li> <li> If you take XARELTO<sup>®</sup> during pregnancy, tell your doctor right away if you have any signs or symptoms of bleeding or blood loss. See “What is the most important information I should know about XARELTO<sup>®</sup>?” for signs and symptoms of bleeding. </li> </ul> </li> <li> Are breastfeeding or plan to breastfeed. XARELTO<sup>®</sup> may pass into your breast milk. Talk to your doctor about the best way to feed your baby during treatment with XARELTO<sup>®</sup>. </li> </ul> <p> Tell all of your doctors and dentists that you are taking XARELTO<sup>®</sup>. They should talk to the doctor who prescribed XARELTO<sup>®</sup> for you before you have any surgery, medical or dental procedure. </p> <p> Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements<b>. </b> </p> <p> Some of your other medicines may affect the way XARELTO<sup>®</sup> works, causing side effects. Certain medicines may increase your risk of bleeding. See “What is the most important information I should know about XARELTO<sup>®</sup>?” </p> <p> HOW SHOULD I TAKE XARELTO<sup>®</sup>? </p> <ul > <li> Take XARELTO<sup>®</sup> exactly as prescribed by your doctor. </li> <li> Do not change your dose or stop taking XARELTO<sup>®</sup> unless your doctor tells you to. Your doctor may change your dose if needed. </li> <li> Your doctor will decide how long you should take XARELTO<sup>®</sup>. </li> <li> XARELTO<sup>®</sup> may need to be stopped for one or more days before any surgery or medical or dental procedure. Your doctor will tell you when to stop taking XARELTO<sup>®</sup> and when to start taking XARELTO<sup>®</sup> again after your surgery or procedure. </li> <li> If you need to stop taking XARELTO<sup>®</sup> for any reason, talk to the doctor who prescribed XARELTO<sup>®</sup> to you to find out when you should stop taking it. Do not stop taking XARELTO<sup>®</sup> without first talking to the doctor who prescribes it to you. </li> <li> If you have difficulty swallowing XARELTO<sup>®</sup> tablets whole, talk to your doctor about other ways to take XARELTO<sup>®</sup>. </li> <li> Do not run out of XARELTO<sup>®</sup>. Refill your prescription of XARELTO<sup>®</sup> before you run out. When leaving the hospital following a hip or knee replacement, be sure that you will have XARELTO<sup>®</sup> available to avoid missing any doses. </li> <li> If you take too much XARELTO<sup>®</sup>, go to the nearest hospital emergency room or call your doctor right away. </li> </ul> <p > If you take XARELTO<sup>®</sup> for:​ </p> <ul > <ul > <li > Atrial Fibrillation that is not caused by a heart valve problem: <ul > <li > Take XARELTO<sup>®</sup> 1 time a day with your evening meal. </li> <li > If you miss a dose of XARELTO<sup>®</sup>, take it as soon as you remember on the same day. Take your next dose at your regularly scheduled time. </li> </ul> </li> <li > Blood clots in the veins of your legs or lungs: <ul > <li > Take XARELTO<sup>® </sup>1 or 2 times a day as prescribed by your doctor. </li> <li > For the 10-mg dose, XARELTO<sup>®</sup> may be taken with or without food. </li> <li > For the 15-mg and 20-mg doses, take XARELTO<sup>®</sup> with food at the same time each day. </li> <li > If you miss a dose: <ul > <li> If you take the 15-mg dose of XARELTO<sup>®</sup> 2 times a day (a total of 30 mg of XARELTO<sup>®</sup> in 1 day): Take XARELTO<sup>®</sup> as soon as you remember on the same day. You may take 2 doses at the same time to make up for the missed dose. Take your next dose at your regularly scheduled time. </li> <li> If you take XARELTO<sup>®</sup> 1 time a day: Take XARELTO<sup>®</sup> as soon as you remember on the same day. Take your next dose at your regularly scheduled time.​ </li> </ul> </li> </ul> </li> <li > Hip or knee replacement surgery: <ul > <li > Take XARELTO<sup>®</sup> 1 time a day with or without food. </li> <li > If you miss a dose of XARELTO<sup>®</sup>, take it as soon as you remember on the same day. Take your next dose at your regularly scheduled time. </li> </ul> </li> <li > Blood clots in people hospitalized for an acute illness: <ul> <li > Take XARELTO<sup>®</sup> 1 time a day, with or without food, while you are in the hospital and after you are discharged as prescribed by your doctor. </li> <li > If you miss a dose of XARELTO<sup>®</sup>, take it as soon as you remember on the same day. Take your next dose at your regularly scheduled time. </li> </ul> </li> <li > Reducing the risk of serious heart problems, heart attack and stroke in coronary artery disease or peripheral artery disease: <ul> <li > Take XARELTO<sup>®</sup> 2.5 mg 2 times a day with or without food. </li> <li > If you miss a dose of XARELTO<sup>®</sup>, take your next dose at your regularly scheduled time. </li> <li > Take aspirin 75 to 100 mg once daily as instructed by your doctor. </li> </ul> </li> </ul> </ul> <div > <p> WHAT ARE THE POSSIBLE SIDE EFFECTS OF <span >XARELTO<sup>®</sup>?</span> </p> <p > XARELTO<sup>®</sup> may cause serious side effects: </p> <ul> <li> See “What is the most important information I should know about XARELTO<sup>®</sup>?” </li> </ul> <p> The most common side effect of XARELTO<sup>®</sup> was bleeding. </p> <p> Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects to Janssen Pharmaceuticals, Inc., at 1-800-JANSSEN (1-800-526-7736). </p> <p> Please read full Prescribing Information, including Boxed Warnings, and Medication Guide for XARELTO<sup>®</sup>. </p> <p> Trademarks are those of their respective owners. </p> <p > cp-53637v6 </p> </div> </div> </div> </div> </div></div><div > <div > <p>© Janssen Pharmaceuticals, Inc. 2021May 2021cp-113688v4</p> </div> </div></div></div> <main > </main> <div ><div ><div >WebMD does not endorse any specific product, service, or treatment.</div></div><div ><div > <div > Show More </div> <div > <div ><div > <div > <div > <div > <div > <div > WHAT IS XARELTO<sup>®</sup> (rivaroxaban)?</div> <div > <p>XARELTO<sup>®</sup> is a prescription medicine used to:</p> <ul> <li> reduce the risk of stroke and blood clots in people who have a medical condition called atrial fibrillation that is not caused by a heart valve problem. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to the formation of blood clots, which can travel to the brain, causing a stroke, or to other parts of the body </li> <li> treat blood clots in the veins of your legs (deep vein thrombosis or DVT) or lungs (pulmonary embolism or PE) </li> <li> reduce the risk of blood clots happening again in people who continue to be at risk for DVT or PE after receiving treatment for blood clots for at least 6 months </li> </ul> <p>XARELTO<sup>®</sup> is used with low dose aspirin to:</p> <ul> <li> reduce the risk of serious heart problems, heart attack and stroke in people with coronary artery disease (a condition where the blood supply to the heart is reduced or blocked) or peripheral artery disease (a condition where the blood flow to the legs is reduced) </li> </ul> <p>It is not known if XARELTO<sup>®</sup> is safe and effective in children.</p> </div> </div> <div > <div >WHAT IS XARELTO<sup>®</sup> (rivaroxaban)?</div> <div > <p>XARELTO<sup>®</sup> is a prescription medicine used to:</p> <ul> <li>reduce the risk of stroke and blood clots in people who have a medical condition called atrial fibrillation that is not caused by a heart valve problem. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to the formation of blood clots, which can travel to the brain, causing a stroke, or to other parts of the body</li> </ul> <p>It is not known if XARELTO<sup>®</sup> is safe and effective in children.</p> </div> </div> <div > <div >WHAT IS XARELTO<sup>®</sup> (rivaroxaban)?</div> <div > <p>XARELTO<sup>®</sup> is a prescription medicine used to:</p> <ul> <li>treat blood clots in the veins of your legs (deep vein thrombosis or DVT) or lungs (pulmonary embolism or PE)</li> <li>reduce the risk of blood clots happening again in people who continue to be at risk for DVT or PE after receiving treatment for blood clots for at least 6 months</li> </ul> <p>It is not known if XARELTO<sup>®</sup> is safe and effective in children.</p> </div> </div> <div > <div >WHAT IS XARELTO<sup>®</sup> (rivaroxaban)?</div> <div > <p>XARELTO<sup>®</sup> is a prescription medicine used with low dose aspirin to:</p> <ul> <li>reduce the risk of serious heart problems, heart attack and stroke in people with coronary artery disease (a condition where the blood supply to the heart is reduced or blocked) or peripheral artery disease (a condition where the blood flow to the legs is reduced) </li> </ul> <p>It is not known if XARELTO<sup>®</sup> is safe and effective in children.</p> </div> </div> </div> <div > <h3 >IMPORTANT SAFETY INFORMATION</h3> <p >WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT XARELTO<sup>®</sup>?</p> <p> XARELTO<sup>®</sup> may cause serious side effects, including: </p> <ul > <li> Increased risk of blood clots if you stop taking XARELTO<sup>®</sup>. People with atrial fibrillation (an irregular heart beat) that is not caused by a heart valve problem (nonvalvular) are at an increased risk of forming a blood clot in the heart, which can travel to the brain, causing a stroke, or to other parts of the body. XARELTO<sup>®</sup> lowers your chance of having a stroke by helping to prevent clots from forming. If you stop taking XARELTO<sup>®</sup>, you may have increased risk of forming a clot in your blood. </li> <li > Do not stop taking XARELTO<sup>®</sup> without talking to the doctor who prescribes it for you. Stopping XARELTO<sup>®</sup> increases your risk of having a stroke. If you have to stop taking XARELTO<sup>®</sup>, your doctor may prescribe another blood thinner medicine to prevent a blood clot from forming. </li> <li> Increased risk of bleeding. XARELTO<sup>®</sup> can cause bleeding which can be serious, and may lead to death. This is because XARELTO<sup>®</sup> is a blood thinner medicine (anticoagulant) that lowers blood clotting. During treatment with XARELTO<sup>®</sup> you are likely to bruise more easily, and it may take longer for bleeding to stop. You may be at higher risk of bleeding if you take XARELTO<sup>®</sup> and have certain other medical problems. </li> </ul> <p > You may have a higher risk of bleeding if you take XARELTO<sup>®</sup> and take other medicines that increase your risk of bleeding, including: </p> <ul > <li>Aspirin or aspirin-containing products</li> <li>Long-term (chronic) use of non-steroidal anti-inflammatory drugs (NSAIDs)</li> <li>Warfarin sodium (Coumadin<sup>®</sup>, Jantoven<sup>®</sup>)</li> <li>Any medicine that contains heparin</li> <li>Clopidogrel (Plavix<sup>®</sup>)</li> <li>Selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs)</li> <li>Other medicines to prevent or treat blood clots</li> </ul> <p > Tell your doctor if you take any of these medicines. Ask your doctor or pharmacist if you are not sure if your medicine is one listed above. </p> <p > Call your doctor or get medical help right away if you develop any of these signs or symptoms of bleeding: </p> <ul > <li>Unexpected bleeding or bleeding that lasts a long time, such as:</li> </ul> <ul > <li>Nosebleeds that happen often</li> <li>Unusual bleeding from gums</li> <li>Menstrual bleeding that is heavier than normal, or vaginal bleeding</li> </ul> <ul > <li>Bleeding that is severe or you cannot control</li> <li>Red, pink, or brown urine</li> <li>Bright red or black stools (looks like tar)</li> <li>Cough up blood or blood clots</li> <li>Vomit blood or your vomit looks like "coffee grounds"</li> <li>Headaches, feeling dizzy or weak</li> <li >Pain, swelling, or new drainage at wound sites</li> </ul> <li > Spinal or epidural blood clots (hematoma). People who take a blood thinner medicine (anticoagulant) like XARELTO<sup>®</sup>, and have medicine injected into their spinal and epidural area, or have a spinal puncture, have a risk of forming a blood clot that can cause long-term or permanent loss of the ability to move (paralysis). Your risk of developing a spinal or epidural blood clot is higher if: <ul > <li> A thin tube called an epidural catheter is placed in your back to give you certain medicine </li> <li> You take NSAIDs or a medicine to prevent blood from clotting </li> <li> You have a history of difficult or repeated epidural or spinal punctures </li> <li> You have a history of problems with your spine or have had surgery on your spine </li> </ul> </li> <p > If you take XARELTO<sup>®</sup> and receive spinal anesthesia or have a spinal puncture, your doctor should watch you closely for symptoms of spinal or epidural blood clots. Tell your doctor right away if you have back pain, tingling, numbness, muscle weakness (especially in your legs and feet), or loss of control of the bowels or bladder (incontinence). </p> <p> XARELTO<sup>®</sup> is not for use in people with artificial heart valves. </p> <p> XARELTO<sup>®</sup> is not for use in people with antiphospholipid syndrome (APS), especially with positive triple antibody testing. </p> <p > ​​Do not take XARELTO<sup>®</sup> if you: </p> <ul > <li> Currently have certain types of abnormal bleeding. Talk to your doctor before taking XARELTO<sup>®</sup> if you currently have unusual bleeding. </li> <li> Are allergic to rivaroxaban or any of the ingredients of XARELTO<sup>®</sup>. </li> </ul> <p > ​​Before taking XARELTO<sup>®</sup>, tell your doctor about all your medical conditions, including if you: </p> <ul > <li> Have ever had bleeding problems </li> <li> Have liver or kidney problems </li> <li> Have antiphospholipid syndrome (APS) </li> <li> Are pregnant or plan to become pregnant. It is not known if XARELTO<sup>®</sup> will harm your unborn baby. <ul> <li> Tell your doctor right away if you become pregnant during treatment with XARELTO<sup>®</sup>. Taking XARELTO<sup>®</sup> while you are pregnant may increase the risk of bleeding in you or in your unborn baby. </li> <li> If you take XARELTO<sup>®</sup> during pregnancy, tell your doctor right away if you have any signs or symptoms of bleeding or blood loss. See “What is the most important information I should know about XARELTO<sup>®</sup>?” for signs and symptoms of bleeding. </li> </ul> </li> <li> Are breastfeeding or plan to breastfeed. XARELTO<sup>®</sup> may pass into your breast milk. Talk to your doctor about the best way to feed your baby during treatment with XARELTO<sup>®</sup>. </li> </ul> <p> Tell all of your doctors and dentists that you are taking XARELTO<sup>®</sup>. They should talk to the doctor who prescribed XARELTO<sup>®</sup> for you before you have any surgery, medical or dental procedure. </p> <p> Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements<b>. </b> </p> <p> Some of your other medicines may affect the way XARELTO<sup>®</sup> works, causing side effects. Certain medicines may increase your risk of bleeding. See “What is the most important information I should know about XARELTO<sup>®</sup>?” </p> <p> HOW SHOULD I TAKE XARELTO<sup>®</sup>? </p> <ul > <li> Take XARELTO<sup>®</sup> exactly as prescribed by your doctor. </li> <li> Do not change your dose or stop taking XARELTO<sup>®</sup> unless your doctor tells you to. Your doctor may change your dose if needed. </li> <li> Your doctor will decide how long you should take XARELTO<sup>®</sup>. </li> <li> XARELTO<sup>®</sup> may need to be stopped for one or more days before any surgery or medical or dental procedure. Your doctor will tell you when to stop taking XARELTO<sup>®</sup> and when to start taking XARELTO<sup>®</sup> again after your surgery or procedure. </li> <li> If you need to stop taking XARELTO<sup>®</sup> for any reason, talk to the doctor who prescribed XARELTO<sup>®</sup> to you to find out when you should stop taking it. Do not stop taking XARELTO<sup>®</sup> without first talking to the doctor who prescribes it to you. </li> <li> If you have difficulty swallowing XARELTO<sup>®</sup> tablets whole, talk to your doctor about other ways to take XARELTO<sup>®</sup>. </li> <li> Do not run out of XARELTO<sup>®</sup>. Refill your prescription of XARELTO<sup>®</sup> before you run out. When leaving the hospital following a hip or knee replacement, be sure that you will have XARELTO<sup>®</sup> available to avoid missing any doses. </li> <li> If you take too much XARELTO<sup>®</sup>, go to the nearest hospital emergency room or call your doctor right away. </li> </ul> <p > If you take XARELTO<sup>®</sup> for:​ </p> <ul > <ul > <li > Atrial Fibrillation that is not caused by a heart valve problem: <ul > <li > Take XARELTO<sup>®</sup> 1 time a day with your evening meal. </li> <li > If you miss a dose of XARELTO<sup>®</sup>, take it as soon as you remember on the same day. Take your next dose at your regularly scheduled time. </li> </ul> </li> <li > Blood clots in the veins of your legs or lungs: <ul > <li > Take XARELTO<sup>® </sup>1 or 2 times a day as prescribed by your doctor. </li> <li > For the 10-mg dose, XARELTO<sup>®</sup> may be taken with or without food. </li> <li > For the 15-mg and 20-mg doses, take XARELTO<sup>®</sup> with food at the same time each day. </li> <li > If you miss a dose: <ul > <li> If you take the 15-mg dose of XARELTO<sup>®</sup> 2 times a day (a total of 30 mg of XARELTO<sup>®</sup> in 1 day): Take XARELTO<sup>®</sup> as soon as you remember on the same day. You may take 2 doses at the same time to make up for the missed dose. Take your next dose at your regularly scheduled time. </li> <li> If you take XARELTO<sup>®</sup> 1 time a day: Take XARELTO<sup>®</sup> as soon as you remember on the same day. Take your next dose at your regularly scheduled time.​ </li> </ul> </li> </ul> </li> <li > Hip or knee replacement surgery: <ul > <li > Take XARELTO<sup>®</sup> 1 time a day with or without food. </li> <li > If you miss a dose of XARELTO<sup>®</sup>, take it as soon as you remember on the same day. Take your next dose at your regularly scheduled time. </li> </ul> </li> <li > Blood clots in people hospitalized for an acute illness: <ul> <li > Take XARELTO<sup>®</sup> 1 time a day, with or without food, while you are in the hospital and after you are discharged as prescribed by your doctor. </li> <li > If you miss a dose of XARELTO<sup>®</sup>, take it as soon as you remember on the same day. Take your next dose at your regularly scheduled time. </li> </ul> </li> <li > Reducing the risk of serious heart problems, heart attack and stroke in coronary artery disease or peripheral artery disease: <ul> <li > Take XARELTO<sup>®</sup> 2.5 mg 2 times a day with or without food. </li> <li > If you miss a dose of XARELTO<sup>®</sup>, take your next dose at your regularly scheduled time. </li> <li > Take aspirin 75 to 100 mg once daily as instructed by your doctor. </li> </ul> </li> </ul> </ul> <div > <p> WHAT ARE THE POSSIBLE SIDE EFFECTS OF <span >XARELTO<sup>®</sup>?</span> </p> <p > XARELTO<sup>®</sup> may cause serious side effects: </p> <ul> <li> See “What is the most important information I should know about XARELTO<sup>®</sup>?” </li> </ul> <p> The most common side effect of XARELTO<sup>®</sup> was bleeding. </p> <p> Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects to Janssen Pharmaceuticals, Inc., at 1-800-JANSSEN (1-800-526-7736). </p> <p> Please read full <a >Prescribing Information</a>, including Boxed Warnings, and <a >Medication Guide</a> for XARELTO<sup>®</sup>. </p> <p> Trademarks are those of their respective owners. </p> <p > cp-53637v6 </p> </div> </div> </div> </div> </div></div> </div> </div> </div></div> </body>'</script>

      </head>
        <body class="valid" valid="valid" title="valid: True, node: 1, level: 1" node_number="1"> <header class="valid" valid="valid" title="valid: True, node: 2, level: 2" node_number="2"/> <div class="valid" valid="valid" title="valid: True, node: 3, level: 2" node_number="3"><div class="valid" valid="valid" title="valid: True, node: 4, level: 3" node_number="4"><div class="valid" valid="valid" title="valid: True, node: 5, level: 4" node_number="5"> <div class="valid" valid="valid" title="valid: True, node: 6, level: 5" node_number="6"> <div class="valid" valid="valid" title="valid: True, node: 7, level: 6" node_number="7"> <h1 class="valid" valid="valid" title="valid: True, node: 8, level: 7" node_number="8"><a class="valid" valid="valid" title="valid: True, node: 9, level: 8" node_number="9">THE TURNING POINT</a></h1> <div class="valid" valid="valid" title="valid: True, node: 10, level: 7" node_number="10"> <ul class="valid" valid="valid" title="valid: True, node: 11, level: 8" node_number="11"> <li class="valid" valid="valid" title="valid: True, node: 12, level: 9" node_number="12"> <a class="valid" valid="valid" title="valid: True, node: 13, level: 10" node_number="13"> AFIB </a> </li> <li class="valid" valid="valid" title="valid: True, node: 14, level: 9" node_number="14"> <a class="valid" valid="valid" title="valid: True, node: 15, level: 10" node_number="15"> DVT/PE </a> </li> <li class="valid" valid="valid" title="valid: True, node: 16, level: 9" node_number="16"> <a class="valid" valid="valid" title="valid: True, node: 17, level: 10" node_number="17"> CAD </a> </li> </ul> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 18, level: 6" node_number="18"> <div class="valid" valid="valid" title="valid: True, node: 19, level: 7" node_number="19"> <div class="valid" valid="valid" title="valid: True, node: 20, level: 8" node_number="20"> <div class="valid" valid="valid" title="valid: True, node: 21, level: 9" node_number="21"> <p class="valid" valid="valid" title="valid: True, node: 22, level: 10" node_number="22">Finding resilience after recurring events</p> <div class="valid" valid="valid" title="valid: True, node: 23, level: 10" node_number="23"> <p class="valid" valid="valid" title="valid: True, node: 24, level: 11" node_number="24">JOE</p> <p class="valid" valid="valid" title="valid: True, node: 25, level: 11" node_number="25">Age 68</p> <p class="valid" valid="valid" title="valid: True, node: 26, level: 11" node_number="26">Diagnosed with DVT/PE in 2012</p> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 27, level: 8" node_number="27"> <div class="valid" valid="valid" title="valid: True, node: 28, level: 9" node_number="28"> <p class="valid" valid="valid" title="valid: True, node: 29, level: 10" node_number="29">Joe is a 68-year-old retiree who lives in Hawaii. He spends his time going to the beach, fishing, cycling, and gardening with his wife. By the looks of it, you would never know that Joe has suffered from recurring pulmonary embolisms (PE). His first one occurred in the middle of the night after a flight from Hawaii to Arizona. "I woke up and couldn't take a full breath, so I went to the emergency room," Joe said. There, the doctor asked Joe if he was having trouble with his left leg and if he had recently been on an airplane for an extended period. The answer to both was yes, and after "a battery of tests," Joe's doctors determined he had a PE. "I was surprised and very overwhelmed," Joe said. "There had been a knot in my left leg. I did the normal thing. Massage the muscle. Soak it in hot water. I did all those kind of things&#8230;and nothing seemed to work. [Had] I known about pulmonary embolisms, I probably would've got up and walked around, drank more water, all the things that I do now [while traveling]." Joe was prescribed warfarin to treat and help reduce the risk of another PE.</p> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 30, level: 7" node_number="30"> What is DVT/PE? <p class="valid" valid="valid" title="valid: True, node: 31, level: 8" node_number="31">A PE occurs when a blood clot called a deep vein thrombosis (DVT) forms and travels to your lungs. DVT forms in a vein deep inside your body, such as in the legs. DVT is the third most common vascular diagnosis behind heart attack and stroke. It affects between 300,000 and 600,000 people in the US every year.</p> <div class="valid" valid="valid" title="valid: True, node: 32, level: 8" node_number="32"> <div class="valid" valid="valid" title="valid: True, node: 33, level: 9" node_number="33"> <div class="valid" valid="valid" title="valid: True, node: 34, level: 10" node_number="34"> <p class="valid" valid="valid" title="valid: True, node: 35, level: 11" node_number="35">An estimated 60,000-100,000 Americans DIE OF DVT/PE every year.</p> </div> <div class="valid" valid="valid" title="valid: True, node: 36, level: 10" node_number="36"> <p class="valid" valid="valid" title="valid: True, node: 37, level: 11" node_number="37">Up to 12% of future DVT or PE blood clots RESULT IN A FATAL PE. </p> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 38, level: 8" node_number="38"> Risk Factors <p class="valid" valid="valid" title="valid: True, node: 39, level: 9" node_number="39">Certain people are at higher risk for DVT/PE events: those who smoke, are over the age of 60, overweight, pregnant, or have a family history of blood clots. Slow blood flow due to immobility during extended travel, having a recent injury or surgery, and taking hormone medications are also risk factors. Joe met several of these criteria and experienced some telltale symptoms, which helped his doctors diagnose him. "Unexplained acute cough, especially if associated with blood, new and sudden shortness of breath, low oxygen levels, and, in extreme situations, cramping of the calf muscle, chest pain, passing out, or vision changes" are signs to watch out for, according to Dr. Kamran Boka, a pulmonary attending physician.</p> </div> <div class="valid" valid="valid" title="valid: True, node: 40, level: 8" node_number="40"> <div class="valid" valid="valid" title="valid: True, node: 41, level: 9" node_number="41"><h2 class="valid" valid="valid" title="valid: True, node: 42, level: 10" node_number="42">FAMILIARIZE YOURSELF WITH THE RISK FACTORS</h2></div> <div class="valid" valid="valid" title="valid: True, node: 43, level: 9" node_number="43"> <div class="valid" valid="valid" title="valid: True, node: 44, level: 10" node_number="44"> <h3 class="valid" valid="valid" title="valid: True, node: 45, level: 11" node_number="45">SLOW BLOOD FLOW</h3> <ul class="valid" valid="valid" title="valid: True, node: 46, level: 11" node_number="46"> <li class="valid" valid="valid" title="valid: True, node: 47, level: 12" node_number="47">During extended travel</li> <li class="valid" valid="valid" title="valid: True, node: 48, level: 12" node_number="48">After surgery</li> <li class="valid" valid="valid" title="valid: True, node: 49, level: 12" node_number="49">During illness</li> </ul> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 50, level: 9" node_number="50"> <div class="valid" valid="valid" title="valid: True, node: 51, level: 10" node_number="51"> <h3 class="valid" valid="valid" title="valid: True, node: 52, level: 11" node_number="52">CERTAIN MEDICATIONS</h3> <ul class="valid" valid="valid" title="valid: True, node: 53, level: 11" node_number="53"> <li class="valid" valid="valid" title="valid: True, node: 54, level: 12" node_number="54">Oral contraceptives</li> <li class="valid" valid="valid" title="valid: True, node: 55, level: 12" node_number="55">Hormone therapy</li> <li class="valid" valid="valid" title="valid: True, node: 56, level: 12" node_number="56">Cancer treatments</li> </ul> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 57, level: 9" node_number="57"> <div class="valid" valid="valid" title="valid: True, node: 58, level: 10" node_number="58"> <h3 class="valid" valid="valid" title="valid: True, node: 59, level: 11" node_number="59">CERTAIN CHARACTERISTICS</h3> <ul class="valid" valid="valid" title="valid: True, node: 60, level: 11" node_number="60"> <li class="valid" valid="valid" title="valid: True, node: 61, level: 12" node_number="61">Being overweight</li> <li class="valid" valid="valid" title="valid: True, node: 62, level: 12" node_number="62">Smoking</li> <li class="valid" valid="valid" title="valid: True, node: 63, level: 12" node_number="63">Being over 60 years of age</li> </ul> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 64, level: 9" node_number="64"> <div class="valid" valid="valid" title="valid: True, node: 65, level: 10" node_number="65"> <h3 class="valid" valid="valid" title="valid: True, node: 66, level: 11" node_number="66">INJURY TO A DEEP VEIN</h3> <ul class="valid" valid="valid" title="valid: True, node: 67, level: 11" node_number="67"> <li class="valid" valid="valid" title="valid: True, node: 68, level: 12" node_number="68">Surgery</li> <li class="valid" valid="valid" title="valid: True, node: 69, level: 12" node_number="69">Trauma</li> </ul> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 70, level: 9" node_number="70"> <div class="valid" valid="valid" title="valid: True, node: 71, level: 10" node_number="71"> <h3 class="valid" valid="valid" title="valid: True, node: 72, level: 11" node_number="72">MEDICAL HISTORY</h3> <ul class="valid" valid="valid" title="valid: True, node: 73, level: 11" node_number="73"> <li class="valid" valid="valid" title="valid: True, node: 74, level: 12" node_number="74">Blood clotting disorders</li> <li class="valid" valid="valid" title="valid: True, node: 75, level: 12" node_number="75">Family history of blood clots</li> </ul> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 76, level: 9" node_number="76"> <div class="valid" valid="valid" title="valid: True, node: 77, level: 10" node_number="77"> <p class="valid" valid="valid" title="valid: True, node: 78, level: 11" node_number="78">If you've already had a DVT or PE, YOUR RISK FOR ANOTHER INCREASES OVER TIME.</p> </div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 79, level: 7" node_number="79"> <div class="valid" valid="valid" title="valid: True, node: 80, level: 8" node_number="80"> <h3 class="valid" valid="valid" title="valid: True, node: 81, level: 9" node_number="81">Joe's Turning Point</h3> </div> <div class="valid" valid="valid" title="valid: True, node: 82, level: 8" node_number="82"> <p class="valid" valid="valid" title="valid: True, node: 83, level: 9" node_number="83">Unfortunately, Joe's first PE was not his last. "The disheartening thing is once you have one, you're more susceptible to have another one," Joe said. A year later, he was setting up chairs for an event when he started feeling the same sensation in his chest that he felt the night of his first PE. Immediately, Joe knew what was happening and went to the hospital, where he was diagnosed with another PE. There were no obvious causes for this event, so Joe continued taking warfarin, the medication initially prescribed for his condition, until he had yet another PE blood clot event the next year. That's when he and his doctors decided to revisit his treatment plan.</p> <p class="valid" valid="valid" title="valid: True, node: 84, level: 9" node_number="84">There are different types of blood thinners that treat DVT/PE. Anticoagulants help prevent or reduce blood clotting, and antiplatelet drugs help keep platelets (a type of blood cell) from sticking together and forming a clot.</p> <div class="valid" valid="valid" title="valid: True, node: 85, level: 9" node_number="85"> <p class="valid" valid="valid" title="valid: True, node: 86, level: 10" node_number="86">&#8220;We want to reduce the stickiness of the blood and prevent existing clots from getting bigger. Anticoagulation blocks clotting and reduces that from happening."</p> <p class="valid" valid="valid" title="valid: True, node: 87, level: 10" node_number="87">Dr. Kamran Boka</p> </div> <p class="valid" valid="valid" title="valid: True, node: 88, level: 9" node_number="88">Joe's doctors recommended he start taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 89, level: 10" node_number="89">&#174;</sup>, a blood thinner prescribed to treat and reduce the risk of DVT/PE blood clots from happening again. "I was happy to get it and happy to get on with my life," Joe said. "Getting back [to your life] after you've had a PE is the place every patient wants to be."</p> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 90, level: 7" node_number="90"> <div class="valid" valid="valid" title="valid: True, node: 91, level: 8" node_number="91"> <div class="valid" valid="valid" title="valid: True, node: 92, level: 9" node_number="92"> <div class="valid" valid="valid" title="valid: True, node: 93, level: 10" node_number="93"> <div class="valid" valid="valid" title="valid: True, node: 94, level: 11" node_number="94"> <h2 class="valid" valid="valid" title="valid: True, node: 95, level: 12" node_number="95">How do I know if I'm at risk for a DVT or PE event?</h2> <p class="valid" valid="valid" title="valid: True, node: 96, level: 12" node_number="96">Deep vein thrombosis (DVT) and pulmonary embolism (PE) blood clot events can be unexpected and scary, and there are several risk factors known to increase the possibility of a DVT/PE event.</p> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 97, level: 10" node_number="97"> <div class="valid" valid="valid" title="valid: True, node: 98, level: 11" node_number="98"> <h2 class="valid" valid="valid" title="valid: True, node: 99, level: 12" node_number="99">What are the symptoms of DVT?</h2> <p class="valid" valid="valid" title="valid: True, node: 100, level: 12" node_number="100">A common symptom is swelling in the affected limb, which is usually in the leg.</p> <p class="valid" valid="valid" title="valid: True, node: 101, level: 12" node_number="101">You might also feel cramping that turns into pain, skin that is warm to the touch, or see red or discolored skin.</p> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 102, level: 10" node_number="102"> <div class="valid" valid="valid" title="valid: True, node: 103, level: 11" node_number="103"> <h2 class="valid" valid="valid" title="valid: True, node: 104, level: 12" node_number="104">What are the symptoms of PE?</h2> <p class="valid" valid="valid" title="valid: True, node: 105, level: 12" node_number="105">Symptoms include sudden or unexplained shortness of breath, rapid breathing, chest pain under the rib cage that may worsen with deep breaths, feeling lightheaded, or coughing up blood. </p> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 106, level: 10" node_number="106"> <div class="valid" valid="valid" title="valid: True, node: 107, level: 11" node_number="107"> <h2 class="valid" valid="valid" title="valid: True, node: 108, level: 12" node_number="108">What are the consequences?</h2> <p class="valid" valid="valid" title="valid: True, node: 109, level: 12" node_number="109">PE is actually a complication of DVT and occurs when the DVT blood clot travels to the lungs. This blocks blood flow to the lungs, which can be life-threatening.</p> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 110, level: 10" node_number="110"> <div class="valid" valid="valid" title="valid: True, node: 111, level: 11" node_number="111"> <h2 class="valid" valid="valid" title="valid: True, node: 112, level: 12" node_number="112">What do I do if I have a DVT or PE event?</h2> <p class="valid" valid="valid" title="valid: True, node: 113, level: 12" node_number="113">If you experience any symptoms of DVT or PE, seek medical attention immediately. This is because a DVT can become a PE, and PEs are often confused with other conditions like pneumonia.</p> <p class="valid" valid="valid" title="valid: True, node: 114, level: 12" node_number="114">It can be difficult for you to determine how serious the situation is. Blood clots can be life-threatening, so it's important to notify your doctor right away. </p> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 115, level: 10" node_number="115"> <div class="valid" valid="valid" title="valid: True, node: 116, level: 11" node_number="116"> <h2 class="valid" valid="valid" title="valid: True, node: 117, level: 12" node_number="117">How can I help prevent a DVT or PE event?</h2> <p class="valid" valid="valid" title="valid: True, node: 118, level: 12" node_number="118">There are simple things you can do to reduce the risk of DVT/PE: avoiding sitting still for long periods, maintaining a healthy weight, staying active, and quitting smoking. </p> <p class="valid" valid="valid" title="valid: True, node: 119, level: 12" node_number="119">However, if you've already had an event, your risk of having another increases over time. In this case, taking blood thinners may help in prevention.</p> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 120, level: 10" node_number="120"> <div class="valid" valid="valid" title="valid: True, node: 121, level: 11" node_number="121"> <h2 class="valid" valid="valid" title="valid: True, node: 122, level: 12" node_number="122">What treatments are available for DVT/PE?</h2> <p class="valid" valid="valid" title="valid: True, node: 123, level: 12" node_number="123">Blood thinners are used to treat DVT/PE blood clots by helping to prevent blood clots from growing larger and helping stop other clots from forming.</p> <p class="valid" valid="valid" title="valid: True, node: 124, level: 12" node_number="124">XARELTO<sup class="valid" valid="valid" title="valid: True, node: 125, level: 13" node_number="125">&#174;</sup> is a blood thinner proven to treat and reduce the risk of DVT/PE blood clots from happening again. In clinical studies, almost 98% of people taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 126, level: 13" node_number="126">&#174;</sup> did not experience another DVT or PE.*</p> <p class="valid" valid="valid" title="valid: True, node: 127, level: 12" node_number="127">XARELTO<sup class="valid" valid="valid" title="valid: True, node: 128, level: 13" node_number="128">&#174;</sup> has no known dietary restrictions and doesn't require regular blood monitoring.</p> <p class="valid" valid="valid" title="valid: True, node: 129, level: 12" node_number="129">*patients were followed for an average of 208 days.</p> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 130, level: 10" node_number="130"> <div class="valid" valid="valid" title="valid: True, node: 131, level: 11" node_number="131"> <h2 class="valid" valid="valid" title="valid: True, node: 132, level: 12" node_number="132">I completed treatment for my initial DVT/PE, am I still at risk? </h2> <p class="valid" valid="valid" title="valid: True, node: 133, level: 12" node_number="133">After completing treatment for an initial DVT or PE, some people remain at risk for another event and may need to continue taking a blood thinner to help reduce their underlying risk. Some may take aspirin to help reduce their risk.</p> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 134, level: 10" node_number="134"> <div class="valid" valid="valid" title="valid: True, node: 135, level: 11" node_number="135"> <h2 class="valid" valid="valid" title="valid: True, node: 136, level: 12" node_number="136">Is aspirin enough to help reduce my risk over time?</h2> <p class="valid" valid="valid" title="valid: True, node: 137, level: 12" node_number="137">Aspirin may not be enough. XARELTO<sup class="valid" valid="valid" title="valid: True, node: 138, level: 13" node_number="138">&#174;</sup> is the only blood thinner that has been studied against aspirin and was proven to significantly reduce the risk of recurrent DVT/PE in people who have completed six months of treatment for an initial event.</p> <p class="valid" valid="valid" title="valid: True, node: 139, level: 12" node_number="139">In a clinical trial, people taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 140, level: 13" node_number="140">&#174;</sup> 10 mg were 3 times less likely to have another DVT or PE compared to people taking aspirin alone.</p> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 141, level: 10" node_number="141"> <div class="valid" valid="valid" title="valid: True, node: 142, level: 11" node_number="142"> <h2 class="valid" valid="valid" title="valid: True, node: 143, level: 12" node_number="143">What else can I do to help reduce my risk of a future DVT/PE blood clot?</h2> <p class="valid" valid="valid" title="valid: True, node: 144, level: 12" node_number="144">Be sure to do your research, maintain healthy habits, know the symptoms, keep in touch with your healthcare team and be sure to take your medication as prescribed.</p> </div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 145, level: 8" node_number="145"> <div class="valid" valid="valid" title="valid: True, node: 146, level: 9" node_number="146"> <div class="valid" valid="valid" title="valid: True, node: 147, level: 10" node_number="147"><p class="valid" valid="valid" title="valid: True, node: 148, level: 11" node_number="148">Blood thinners are used to treat DVT/PE by PREVENTING CLOTS FROM GROWING AND NEW ONES FROM FORMING.</p></div> </div> <div class="valid" valid="valid" title="valid: True, node: 149, level: 9" node_number="149"> <div class="valid" valid="valid" title="valid: True, node: 150, level: 10" node_number="150"><p class="valid" valid="valid" title="valid: True, node: 151, level: 11" node_number="151">Blood thinners may continue to be taken to reduce the risk of future blood clots, even after completion of initial treatment. Work with your doctor to determine your need based on your risk factors.</p></div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 152, level: 8" node_number="152"> <div class="valid" valid="valid" title="valid: True, node: 153, level: 9" node_number="153"> <div class="valid" valid="valid" title="valid: True, node: 154, level: 10" node_number="154"><h3 class="valid" valid="valid" title="valid: True, node: 155, level: 11" node_number="155">AFTER 5 YEARS</h3></div> </div> <div class="valid" valid="valid" title="valid: True, node: 156, level: 9" node_number="156"> <div class="valid" valid="valid" title="valid: True, node: 157, level: 10" node_number="157"><h3 class="valid" valid="valid" title="valid: True, node: 158, level: 11" node_number="158">AFTER 10 YEARS</h3></div> </div> </div> <p class="valid" valid="valid" title="valid: True, node: 159, level: 8" node_number="159">After switching to XARELTO<sup class="valid" valid="valid" title="valid: True, node: 160, level: 9" node_number="160">&#174;</sup> from warfarin, Joe noticed some immediate advantages. "[Warfarin] was problematic [for me] because of the [dietary] restrictions &#8230; And that was something you really had to watch out for," Joe said. "[You also] had to have your blood [tested regularly]. That's something you don't have to do with XARELTO<sup class="valid" valid="valid" title="valid: True, node: 161, level: 9" node_number="161">&#174;</sup>."</p> <p class="valid" valid="valid" title="valid: True, node: 162, level: 8" node_number="162">People taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 163, level: 9" node_number="163">&#174;</sup> will take a higher dose during the first three weeks after a DVT or PE blood clot diagnosis, when the risk of having another one is the highest. </p> <p class="valid" valid="valid" title="valid: True, node: 164, level: 8" node_number="164">If you've had a DVT or PE, your risk of having another one increases over time, particularly once you complete treatment and no longer take a prescription blood thinner. In addition, future events can be more serious&#8212;even life-threatening. Up to 12% of future DVT or PE blood clots result in a fatal PE. XARELTO<sup class="valid" valid="valid" title="valid: True, node: 165, level: 9" node_number="165">&#174;</sup> was the only blood thinner studied vs aspirin that was proven to significantly reduce the risk of recurrent DVT/PE in people who had already completed six months of treatment for an initial event. In a clinical trial, people taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 166, level: 9" node_number="166">&#174;</sup> 10 mg were 3 times less likely to have another DVT or PE compared to people taking aspirin alone.</p> <div class="valid" valid="valid" title="valid: True, node: 167, level: 8" node_number="167"> Maintaining a Positive Outlook <p class="valid" valid="valid" title="valid: True, node: 168, level: 9" node_number="168">Beyond taking his medication, Joe takes steps to stay healthy by eating right and keeping his weight down. "I work out a lot. I cycle. I do as much hiking and walking as I can," Joe said. He also leans on his wife for additional support. "My wife has been very supportive. We support each other in our health. She's more athletic than me, so that keeps me pretty active&#8212;trying to keep up with her." And he is committed to doing what he needs to do to stay healthy. "I just take [my medicine], do what my doctors say, try to stay as healthy as I can and live my life and be happy."</p> <p class="valid" valid="valid" title="valid: True, node: 169, level: 9" node_number="169">If you have had a DVT or PE event, you know how scary it can be; however, it is manageable with treatment. That's why it's important to listen to your body like Joe did and know any symptoms that might indicate a blood clot. Remember, DVT/PE events are often unexpected, and your risk of having another increases over time. Talk to your doctor about treatment options and how to best help lower your risk. </p> </div> <div class="valid" valid="valid" title="valid: True, node: 170, level: 8" node_number="170"> <div class="valid" valid="valid" title="valid: True, node: 171, level: 9" node_number="171"><p class="valid" valid="valid" title="valid: True, node: 172, level: 10" node_number="172">In clinical trials, almost 98% of people taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 173, level: 11" node_number="173">&#174;</sup> DID NOT HAVE ANOTHER DVT OR PE.*</p> <p class="valid" valid="valid" title="valid: True, node: 174, level: 10" node_number="174">*Patients were followed for an average length of treatment of 208 days. </p></div> </div> <div class="valid" valid="valid" title="valid: True, node: 175, level: 8" node_number="175"> <div class="valid" valid="valid" title="valid: True, node: 176, level: 9" node_number="176"><p class="valid" valid="valid" title="valid: True, node: 177, level: 10" node_number="177">YOUR DOCTOR IS ALWAYS YOUR BEST RESOURCE. He or she knows your situation best and can help you determine a treatment plan.</p></div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 178, level: 7" node_number="178"> <div class="valid" valid="valid" title="valid: True, node: 179, level: 8" node_number="179"> <h1 class="valid" valid="valid" title="valid: True, node: 180, level: 9" node_number="180">Find out more about how to help reduce your risk of another DVT or PE with XARELTO<sup class="valid" valid="valid" title="valid: True, node: 181, level: 10" node_number="181">&#174;</sup></h1> Learn More </div> </div> </div> </div> </div> </div><div class="valid" valid="valid" title="valid: True, node: 182, level: 3" node_number="182"><div class="valid" valid="valid" title="valid: True, node: 183, level: 4" node_number="183"> <div class="valid" valid="valid" title="valid: True, node: 184, level: 5" node_number="184"> <div class="valid" valid="valid" title="valid: True, node: 185, level: 6" node_number="185"> <div class="valid" valid="valid" title="valid: True, node: 186, level: 7" node_number="186"> <div class="valid" valid="valid" title="valid: True, node: 187, level: 8" node_number="187"> <div class="valid" valid="valid" title="valid: True, node: 188, level: 9" node_number="188"> <div class="valid" valid="valid" title="valid: True, node: 189, level: 10" node_number="189"> WHAT IS XARELTO<sup class="valid" valid="valid" title="valid: True, node: 190, level: 11" node_number="190">&#174;</sup> (rivaroxaban)?</div> <div class="valid" valid="valid" title="valid: True, node: 191, level: 10" node_number="191"> <p class="valid" valid="valid" title="valid: True, node: 192, level: 11" node_number="192">XARELTO<sup class="valid" valid="valid" title="valid: True, node: 193, level: 12" node_number="193">&#174;</sup> is a prescription medicine used to:</p> <ul class="valid" valid="valid" title="valid: True, node: 194, level: 11" node_number="194"> <li class="valid" valid="valid" title="valid: True, node: 195, level: 12" node_number="195"> reduce the risk of stroke and blood clots in people who have a medical condition called atrial fibrillation that is not caused by a heart valve problem. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to the formation of blood clots, which can travel to the brain, causing a stroke, or to other parts of the body </li> <li class="valid" valid="valid" title="valid: True, node: 196, level: 12" node_number="196"> treat blood clots in the veins of your legs (deep vein thrombosis or DVT) or lungs (pulmonary embolism or PE) </li> <li class="valid" valid="valid" title="valid: True, node: 197, level: 12" node_number="197"> reduce the risk of blood clots happening again in people who continue to be at risk for DVT or PE after receiving treatment for blood clots for at least 6 months </li> </ul> <p class="valid" valid="valid" title="valid: True, node: 198, level: 11" node_number="198">XARELTO<sup class="valid" valid="valid" title="valid: True, node: 199, level: 12" node_number="199">&#174;</sup> is used with low dose aspirin to:</p> <ul class="valid" valid="valid" title="valid: True, node: 200, level: 11" node_number="200"> <li class="valid" valid="valid" title="valid: True, node: 201, level: 12" node_number="201"> reduce the risk of serious heart problems, heart attack and stroke in people with coronary artery disease (a condition where the blood supply to the heart is reduced or blocked) or peripheral artery disease (a condition where the blood flow to the legs is reduced) </li> </ul> <p class="valid" valid="valid" title="valid: True, node: 202, level: 11" node_number="202">It is not known if XARELTO<sup class="valid" valid="valid" title="valid: True, node: 203, level: 12" node_number="203">&#174;</sup> is safe and effective in children.</p> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 204, level: 9" node_number="204"> <div class="valid" valid="valid" title="valid: True, node: 205, level: 10" node_number="205">WHAT IS XARELTO<sup class="valid" valid="valid" title="valid: True, node: 206, level: 11" node_number="206">&#174;</sup> (rivaroxaban)?</div> <div class="valid" valid="valid" title="valid: True, node: 207, level: 10" node_number="207"> <p class="valid" valid="valid" title="valid: True, node: 208, level: 11" node_number="208">XARELTO<sup class="valid" valid="valid" title="valid: True, node: 209, level: 12" node_number="209">&#174;</sup> is a prescription medicine used to:</p> <ul class="valid" valid="valid" title="valid: True, node: 210, level: 11" node_number="210"> <li class="valid" valid="valid" title="valid: True, node: 211, level: 12" node_number="211">reduce the risk of stroke and blood clots in people who have a medical condition called atrial fibrillation that is not caused by a heart valve problem. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to the formation of blood clots, which can travel to the brain, causing a stroke, or to other parts of the body</li> </ul> <p class="valid" valid="valid" title="valid: True, node: 212, level: 11" node_number="212">It is not known if XARELTO<sup class="valid" valid="valid" title="valid: True, node: 213, level: 12" node_number="213">&#174;</sup> is safe and effective in children.</p> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 214, level: 9" node_number="214"> <div class="valid" valid="valid" title="valid: True, node: 215, level: 10" node_number="215">WHAT IS XARELTO<sup class="valid" valid="valid" title="valid: True, node: 216, level: 11" node_number="216">&#174;</sup> (rivaroxaban)?</div> <div class="valid" valid="valid" title="valid: True, node: 217, level: 10" node_number="217"> <p class="valid" valid="valid" title="valid: True, node: 218, level: 11" node_number="218">XARELTO<sup class="valid" valid="valid" title="valid: True, node: 219, level: 12" node_number="219">&#174;</sup> is a prescription medicine used to:</p> <ul class="valid" valid="valid" title="valid: True, node: 220, level: 11" node_number="220"> <li class="valid" valid="valid" title="valid: True, node: 221, level: 12" node_number="221">treat blood clots in the veins of your legs (deep vein thrombosis or DVT) or lungs (pulmonary embolism or PE)</li> <li class="valid" valid="valid" title="valid: True, node: 222, level: 12" node_number="222">reduce the risk of blood clots happening again in people who continue to be at risk for DVT or PE after receiving treatment for blood clots for at least 6 months</li> </ul> <p class="valid" valid="valid" title="valid: True, node: 223, level: 11" node_number="223">It is not known if XARELTO<sup class="valid" valid="valid" title="valid: True, node: 224, level: 12" node_number="224">&#174;</sup> is safe and effective in children.</p> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 225, level: 9" node_number="225"> <div class="valid" valid="valid" title="valid: True, node: 226, level: 10" node_number="226">WHAT IS XARELTO<sup class="valid" valid="valid" title="valid: True, node: 227, level: 11" node_number="227">&#174;</sup> (rivaroxaban)?</div> <div class="valid" valid="valid" title="valid: True, node: 228, level: 10" node_number="228"> <p class="valid" valid="valid" title="valid: True, node: 229, level: 11" node_number="229">XARELTO<sup class="valid" valid="valid" title="valid: True, node: 230, level: 12" node_number="230">&#174;</sup> is a prescription medicine used with low dose aspirin to:</p> <ul class="valid" valid="valid" title="valid: True, node: 231, level: 11" node_number="231"> <li class="valid" valid="valid" title="valid: True, node: 232, level: 12" node_number="232">reduce the risk of serious heart problems, heart attack and stroke in people with coronary artery disease (a condition where the blood supply to the heart is reduced or blocked) or peripheral artery disease (a condition where the blood flow to the legs is reduced) </li> </ul> <p class="valid" valid="valid" title="valid: True, node: 233, level: 11" node_number="233">It is not known if XARELTO<sup class="valid" valid="valid" title="valid: True, node: 234, level: 12" node_number="234">&#174;</sup> is safe and effective in children.</p> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 235, level: 8" node_number="235"> <h3 class="valid" valid="valid" title="valid: True, node: 236, level: 9" node_number="236">IMPORTANT SAFETY INFORMATION</h3> <p class="valid" valid="valid" title="valid: True, node: 237, level: 9" node_number="237">WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT XARELTO<sup class="valid" valid="valid" title="valid: True, node: 238, level: 10" node_number="238">&#174;</sup>?</p> <p class="valid" valid="valid" title="valid: True, node: 239, level: 9" node_number="239"> XARELTO<sup class="valid" valid="valid" title="valid: True, node: 240, level: 10" node_number="240">&#174;</sup> may cause serious side effects, including: </p> <ul class="valid" valid="valid" title="valid: True, node: 241, level: 9" node_number="241"> <li class="valid" valid="valid" title="valid: True, node: 242, level: 10" node_number="242"> Increased risk of blood clots if you stop taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 243, level: 11" node_number="243">&#174;</sup>. People with atrial fibrillation (an irregular heart beat) that is not caused by a heart valve problem (nonvalvular) are at an increased risk of forming a blood clot in the heart, which can travel to the brain, causing a stroke, or to other parts of the body. XARELTO<sup class="valid" valid="valid" title="valid: True, node: 244, level: 11" node_number="244">&#174;</sup> lowers your chance of having a stroke by helping to prevent clots from forming. If you stop taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 245, level: 11" node_number="245">&#174;</sup>, you may have increased risk of forming a clot in your blood. </li> <li class="valid" valid="valid" title="valid: True, node: 246, level: 10" node_number="246"> Do not stop taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 247, level: 11" node_number="247">&#174;</sup> without talking to the doctor who prescribes it for you. Stopping XARELTO<sup class="valid" valid="valid" title="valid: True, node: 248, level: 11" node_number="248">&#174;</sup> increases your risk of having a stroke. If you have to stop taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 249, level: 11" node_number="249">&#174;</sup>, your doctor may prescribe another blood thinner medicine to prevent a blood clot from forming. </li> <li class="valid" valid="valid" title="valid: True, node: 250, level: 10" node_number="250"> Increased risk of bleeding. XARELTO<sup class="valid" valid="valid" title="valid: True, node: 251, level: 11" node_number="251">&#174;</sup> can cause bleeding which can be serious, and may lead to death. This is because XARELTO<sup class="valid" valid="valid" title="valid: True, node: 252, level: 11" node_number="252">&#174;</sup> is a blood thinner medicine (anticoagulant) that lowers blood clotting. During treatment with XARELTO<sup class="valid" valid="valid" title="valid: True, node: 253, level: 11" node_number="253">&#174;</sup> you are likely to bruise more easily, and it may take longer for bleeding to stop. You may be at higher risk of bleeding if you take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 254, level: 11" node_number="254">&#174;</sup> and have certain other medical problems. </li> </ul> <p class="valid" valid="valid" title="valid: True, node: 255, level: 9" node_number="255"> You may have a higher risk of bleeding if you take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 256, level: 10" node_number="256">&#174;</sup> and take other medicines that increase your risk of bleeding, including: </p> <ul class="valid" valid="valid" title="valid: True, node: 257, level: 9" node_number="257"> <li class="valid" valid="valid" title="valid: True, node: 258, level: 10" node_number="258">Aspirin or aspirin-containing products</li> <li class="valid" valid="valid" title="valid: True, node: 259, level: 10" node_number="259">Long-term (chronic) use of non-steroidal anti-inflammatory drugs (NSAIDs)</li> <li class="valid" valid="valid" title="valid: True, node: 260, level: 10" node_number="260">Warfarin sodium (Coumadin<sup class="valid" valid="valid" title="valid: True, node: 261, level: 11" node_number="261">&#174;</sup>, Jantoven<sup class="valid" valid="valid" title="valid: True, node: 262, level: 11" node_number="262">&#174;</sup>)</li> <li class="valid" valid="valid" title="valid: True, node: 263, level: 10" node_number="263">Any medicine that contains heparin</li> <li class="valid" valid="valid" title="valid: True, node: 264, level: 10" node_number="264">Clopidogrel (Plavix<sup class="valid" valid="valid" title="valid: True, node: 265, level: 11" node_number="265">&#174;</sup>)</li> <li class="valid" valid="valid" title="valid: True, node: 266, level: 10" node_number="266">Selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs)</li> <li class="valid" valid="valid" title="valid: True, node: 267, level: 10" node_number="267">Other medicines to prevent or treat blood clots</li> </ul> <p class="valid" valid="valid" title="valid: True, node: 268, level: 9" node_number="268"> Tell your doctor if you take any of these medicines. Ask your doctor or pharmacist if you are not sure if your medicine is one listed above. </p> <p class="valid" valid="valid" title="valid: True, node: 269, level: 9" node_number="269"> Call your doctor or get medical help right away if you develop any of these signs or symptoms of bleeding: </p> <ul class="valid" valid="valid" title="valid: True, node: 270, level: 9" node_number="270"> <li class="valid" valid="valid" title="valid: True, node: 271, level: 10" node_number="271">Unexpected bleeding or bleeding that lasts a long time, such as:</li> </ul> <ul class="valid" valid="valid" title="valid: True, node: 272, level: 9" node_number="272"> <li class="valid" valid="valid" title="valid: True, node: 273, level: 10" node_number="273">Nosebleeds that happen often</li> <li class="valid" valid="valid" title="valid: True, node: 274, level: 10" node_number="274">Unusual bleeding from gums</li> <li class="valid" valid="valid" title="valid: True, node: 275, level: 10" node_number="275">Menstrual bleeding that is heavier than normal, or vaginal bleeding</li> </ul> <ul class="valid" valid="valid" title="valid: True, node: 276, level: 9" node_number="276"> <li class="valid" valid="valid" title="valid: True, node: 277, level: 10" node_number="277">Bleeding that is severe or you cannot control</li> <li class="valid" valid="valid" title="valid: True, node: 278, level: 10" node_number="278">Red, pink, or brown urine</li> <li class="valid" valid="valid" title="valid: True, node: 279, level: 10" node_number="279">Bright red or black stools (looks like tar)</li> <li class="valid" valid="valid" title="valid: True, node: 280, level: 10" node_number="280">Cough up blood or blood clots</li> <li class="valid" valid="valid" title="valid: True, node: 281, level: 10" node_number="281">Vomit blood or your vomit looks like "coffee grounds"</li> <li class="valid" valid="valid" title="valid: True, node: 282, level: 10" node_number="282">Headaches, feeling dizzy or weak</li> <li class="valid" valid="valid" title="valid: True, node: 283, level: 10" node_number="283">Pain, swelling, or new drainage at wound sites</li> </ul> <li class="valid" valid="valid" title="valid: True, node: 284, level: 9" node_number="284"> Spinal or epidural blood clots (hematoma).&#160;People who take a blood thinner medicine (anticoagulant) like XARELTO<sup class="valid" valid="valid" title="valid: True, node: 285, level: 10" node_number="285">&#174;</sup>, and have medicine injected into their spinal and epidural area, or have a spinal puncture, have a risk of forming a blood clot that can cause long-term or permanent loss of the ability to move (paralysis). Your risk of developing a spinal or epidural blood clot is higher if: <ul class="valid" valid="valid" title="valid: True, node: 286, level: 10" node_number="286"> <li class="valid" valid="valid" title="valid: True, node: 287, level: 11" node_number="287"> A thin tube called an epidural catheter is placed in your back to give you certain medicine </li> <li class="valid" valid="valid" title="valid: True, node: 288, level: 11" node_number="288"> You take NSAIDs or a medicine to prevent blood from clotting </li> <li class="valid" valid="valid" title="valid: True, node: 289, level: 11" node_number="289"> You have a history of difficult or repeated epidural or spinal punctures </li> <li class="valid" valid="valid" title="valid: True, node: 290, level: 11" node_number="290"> You have a history of problems with your spine or have had surgery on your spine </li> </ul> </li> <p class="valid" valid="valid" title="valid: True, node: 291, level: 9" node_number="291"> If you take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 292, level: 10" node_number="292">&#174;</sup> and receive spinal anesthesia or have a spinal puncture, your doctor should watch you closely for symptoms of spinal or epidural blood clots. Tell your doctor right away if you have back pain, tingling, numbness, muscle weakness (especially in your legs and feet), or loss of control of the bowels or bladder (incontinence). </p> <p class="valid" valid="valid" title="valid: True, node: 293, level: 9" node_number="293"> XARELTO<sup class="valid" valid="valid" title="valid: True, node: 294, level: 10" node_number="294">&#174;</sup> is not for use in people with artificial heart valves. </p> <p class="valid" valid="valid" title="valid: True, node: 295, level: 9" node_number="295"> XARELTO<sup class="valid" valid="valid" title="valid: True, node: 296, level: 10" node_number="296">&#174;</sup> is not for use in people with antiphospholipid syndrome (APS), especially with positive triple antibody testing. </p> <p class="valid" valid="valid" title="valid: True, node: 297, level: 9" node_number="297"> &#8203;&#8203;Do not take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 298, level: 10" node_number="298">&#174;</sup> if you: </p> <ul class="valid" valid="valid" title="valid: True, node: 299, level: 9" node_number="299"> <li class="valid" valid="valid" title="valid: True, node: 300, level: 10" node_number="300"> Currently have certain types of abnormal bleeding. Talk to your doctor before taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 301, level: 11" node_number="301">&#174;</sup> if you currently have unusual bleeding. </li> <li class="valid" valid="valid" title="valid: True, node: 302, level: 10" node_number="302"> Are allergic to rivaroxaban or any of the ingredients of XARELTO<sup class="valid" valid="valid" title="valid: True, node: 303, level: 11" node_number="303">&#174;</sup>. </li> </ul> <p class="valid" valid="valid" title="valid: True, node: 304, level: 9" node_number="304"> &#8203;&#8203;Before taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 305, level: 10" node_number="305">&#174;</sup>, tell your doctor about all your medical conditions, including if you: </p> <ul class="valid" valid="valid" title="valid: True, node: 306, level: 9" node_number="306"> <li class="valid" valid="valid" title="valid: True, node: 307, level: 10" node_number="307"> Have ever had bleeding problems </li> <li class="valid" valid="valid" title="valid: True, node: 308, level: 10" node_number="308"> Have liver or kidney problems </li> <li class="valid" valid="valid" title="valid: True, node: 309, level: 10" node_number="309"> Have antiphospholipid syndrome (APS) </li> <li class="valid" valid="valid" title="valid: True, node: 310, level: 10" node_number="310"> Are pregnant or plan to become pregnant. It is not known if XARELTO<sup class="valid" valid="valid" title="valid: True, node: 311, level: 11" node_number="311">&#174;</sup> will harm your unborn baby. <ul class="valid" valid="valid" title="valid: True, node: 312, level: 11" node_number="312"> <li class="valid" valid="valid" title="valid: True, node: 313, level: 12" node_number="313"> Tell your doctor right away if you become pregnant during treatment with XARELTO<sup class="valid" valid="valid" title="valid: True, node: 314, level: 13" node_number="314">&#174;</sup>. Taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 315, level: 13" node_number="315">&#174;</sup> while you are pregnant may increase the risk of bleeding in you or in your unborn baby. </li> <li class="valid" valid="valid" title="valid: True, node: 316, level: 12" node_number="316"> If you take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 317, level: 13" node_number="317">&#174;</sup> during pregnancy, tell your doctor right away if you have any signs or symptoms of bleeding or blood loss.&#160;See &#8220;What is the most important information I should know about XARELTO<sup class="valid" valid="valid" title="valid: True, node: 318, level: 13" node_number="318">&#174;</sup>?&#8221; for signs and symptoms of bleeding. </li> </ul> </li> <li class="valid" valid="valid" title="valid: True, node: 319, level: 10" node_number="319"> Are breastfeeding or plan to breastfeed. XARELTO<sup class="valid" valid="valid" title="valid: True, node: 320, level: 11" node_number="320">&#174;</sup> may pass into your breast milk. Talk to your doctor about the best way to feed your baby during treatment with XARELTO<sup class="valid" valid="valid" title="valid: True, node: 321, level: 11" node_number="321">&#174;</sup>. </li> </ul> <p class="valid" valid="valid" title="valid: True, node: 322, level: 9" node_number="322"> Tell all of your doctors and dentists that you are taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 323, level: 10" node_number="323">&#174;</sup>. They should talk to the doctor who prescribed XARELTO<sup class="valid" valid="valid" title="valid: True, node: 324, level: 10" node_number="324">&#174;</sup> for you before you have any surgery, medical or dental procedure. </p> <p class="valid" valid="valid" title="valid: True, node: 325, level: 9" node_number="325"> Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements<b class="valid" valid="valid" title="valid: True, node: 326, level: 10" node_number="326">. </b> </p> <p class="valid" valid="valid" title="valid: True, node: 327, level: 9" node_number="327"> Some of your other medicines may affect the way XARELTO<sup class="valid" valid="valid" title="valid: True, node: 328, level: 10" node_number="328">&#174;</sup> works, causing side effects. Certain medicines may increase your risk of bleeding. See &#8220;What is the most important information I should know about XARELTO<sup class="valid" valid="valid" title="valid: True, node: 329, level: 10" node_number="329">&#174;</sup>?&#8221; </p> <p class="valid" valid="valid" title="valid: True, node: 330, level: 9" node_number="330"> HOW SHOULD I TAKE XARELTO<sup class="valid" valid="valid" title="valid: True, node: 331, level: 10" node_number="331">&#174;</sup>? </p> <ul class="valid" valid="valid" title="valid: True, node: 332, level: 9" node_number="332"> <li class="valid" valid="valid" title="valid: True, node: 333, level: 10" node_number="333"> Take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 334, level: 11" node_number="334">&#174;</sup> exactly as prescribed by your doctor. </li> <li class="valid" valid="valid" title="valid: True, node: 335, level: 10" node_number="335"> Do not change your dose or stop taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 336, level: 11" node_number="336">&#174;</sup> unless your doctor tells you to. Your doctor may change your dose if needed. </li> <li class="valid" valid="valid" title="valid: True, node: 337, level: 10" node_number="337"> Your doctor will decide how long you should take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 338, level: 11" node_number="338">&#174;</sup>. </li> <li class="valid" valid="valid" title="valid: True, node: 339, level: 10" node_number="339"> XARELTO<sup class="valid" valid="valid" title="valid: True, node: 340, level: 11" node_number="340">&#174;</sup> may need to be stopped for one or more days before any surgery or medical or dental procedure. Your doctor will tell you when to stop taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 341, level: 11" node_number="341">&#174;</sup> and when to start taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 342, level: 11" node_number="342">&#174;</sup> again after your surgery or procedure. </li> <li class="valid" valid="valid" title="valid: True, node: 343, level: 10" node_number="343"> If you need to stop taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 344, level: 11" node_number="344">&#174;</sup> for any reason, talk to the doctor who prescribed XARELTO<sup class="valid" valid="valid" title="valid: True, node: 345, level: 11" node_number="345">&#174;</sup> to you to find out when you should stop taking it. Do not stop taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 346, level: 11" node_number="346">&#174;</sup> without first talking to the doctor who prescribes it to you. </li> <li class="valid" valid="valid" title="valid: True, node: 347, level: 10" node_number="347"> If you have difficulty swallowing XARELTO<sup class="valid" valid="valid" title="valid: True, node: 348, level: 11" node_number="348">&#174;</sup> tablets whole, talk to your doctor about other ways to take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 349, level: 11" node_number="349">&#174;</sup>. </li> <li class="valid" valid="valid" title="valid: True, node: 350, level: 10" node_number="350"> Do not run out of XARELTO<sup class="valid" valid="valid" title="valid: True, node: 351, level: 11" node_number="351">&#174;</sup>. Refill your prescription of XARELTO<sup class="valid" valid="valid" title="valid: True, node: 352, level: 11" node_number="352">&#174;</sup> before you run out. When leaving the hospital following a hip or knee replacement, be sure that you will have XARELTO<sup class="valid" valid="valid" title="valid: True, node: 353, level: 11" node_number="353">&#174;</sup> available to avoid missing any doses. </li> <li class="valid" valid="valid" title="valid: True, node: 354, level: 10" node_number="354"> If you take too much XARELTO<sup class="valid" valid="valid" title="valid: True, node: 355, level: 11" node_number="355">&#174;</sup>, go to the nearest hospital emergency room or call your doctor right away. </li> </ul> <p class="valid" valid="valid" title="valid: True, node: 356, level: 9" node_number="356"> If you take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 357, level: 10" node_number="357">&#174;</sup> for:&#8203; </p> <ul class="valid" valid="valid" title="valid: True, node: 358, level: 9" node_number="358"> <ul class="valid" valid="valid" title="valid: True, node: 359, level: 10" node_number="359"> <li class="valid" valid="valid" title="valid: True, node: 360, level: 11" node_number="360"> Atrial Fibrillation that is not caused by a heart valve problem: <ul class="valid" valid="valid" title="valid: True, node: 361, level: 12" node_number="361"> <li class="valid" valid="valid" title="valid: True, node: 362, level: 13" node_number="362"> Take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 363, level: 14" node_number="363">&#174;</sup> 1 time a day with your evening meal. </li> <li class="valid" valid="valid" title="valid: True, node: 364, level: 13" node_number="364"> If you miss a dose of XARELTO<sup class="valid" valid="valid" title="valid: True, node: 365, level: 14" node_number="365">&#174;</sup>, take it as soon as you remember on the same day.&#160;Take your next dose at your regularly scheduled time. </li> </ul> </li> <li class="valid" valid="valid" title="valid: True, node: 366, level: 11" node_number="366"> Blood clots in the veins of your legs or lungs: <ul class="valid" valid="valid" title="valid: True, node: 367, level: 12" node_number="367"> <li class="valid" valid="valid" title="valid: True, node: 368, level: 13" node_number="368"> Take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 369, level: 14" node_number="369">&#174;&#160;</sup>1 or 2 times a day as prescribed by your doctor. </li> <li class="valid" valid="valid" title="valid: True, node: 370, level: 13" node_number="370"> For the 10-mg dose, XARELTO<sup class="valid" valid="valid" title="valid: True, node: 371, level: 14" node_number="371">&#174;</sup> may be taken with or without food. </li> <li class="valid" valid="valid" title="valid: True, node: 372, level: 13" node_number="372"> For the 15-mg and 20-mg doses, take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 373, level: 14" node_number="373">&#174;</sup> with food at the same time each day. </li> <li class="valid" valid="valid" title="valid: True, node: 374, level: 13" node_number="374"> If you miss a dose: <ul class="valid" valid="valid" title="valid: True, node: 375, level: 14" node_number="375"> <li title="valid: False, node: 376, level: 15" node_number="376"> If you take the 15-mg dose of XARELTO<sup title="valid: False, node: 377, level: 16" node_number="377">&#174;</sup> 2 times a day (a total of 30 mg of XARELTO<sup title="valid: False, node: 378, level: 16" node_number="378">&#174;</sup> in 1 day):&#160;Take XARELTO<sup title="valid: False, node: 379, level: 16" node_number="379">&#174;</sup> as soon as you remember on the same day. You may take 2 doses at the same time to make up for the missed dose. Take your next dose at your regularly scheduled time. </li> <li title="valid: False, node: 380, level: 15" node_number="380"> If you take XARELTO<sup title="valid: False, node: 381, level: 16" node_number="381">&#174;</sup> 1 time a day: Take XARELTO<sup title="valid: False, node: 382, level: 16" node_number="382">&#174;</sup> as soon as you remember on the same day. Take your next dose at your regularly scheduled time.&#8203; </li> </ul> </li> </ul> </li> <li class="valid" valid="valid" title="valid: True, node: 383, level: 11" node_number="383"> Hip or knee replacement surgery: <ul class="valid" valid="valid" title="valid: True, node: 384, level: 12" node_number="384"> <li class="valid" valid="valid" title="valid: True, node: 385, level: 13" node_number="385"> Take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 386, level: 14" node_number="386">&#174;</sup> 1 time a day with or without food. </li> <li class="valid" valid="valid" title="valid: True, node: 387, level: 13" node_number="387"> If you miss a dose of XARELTO<sup class="valid" valid="valid" title="valid: True, node: 388, level: 14" node_number="388">&#174;</sup>, take it as soon as you remember on the same day. Take your next dose at your regularly scheduled time. </li> </ul> </li> <li class="valid" valid="valid" title="valid: True, node: 389, level: 11" node_number="389"> Blood clots in people hospitalized for an acute illness: <ul class="valid" valid="valid" title="valid: True, node: 390, level: 12" node_number="390"> <li class="valid" valid="valid" title="valid: True, node: 391, level: 13" node_number="391"> Take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 392, level: 14" node_number="392">&#174;</sup>&#160;1&#160;time a day, with or without food, while you are in the hospital and after you are discharged as prescribed by your doctor. </li> <li class="valid" valid="valid" title="valid: True, node: 393, level: 13" node_number="393"> If you miss a dose of XARELTO<sup class="valid" valid="valid" title="valid: True, node: 394, level: 14" node_number="394">&#174;</sup>, take it as soon as you remember on the same day. Take your next dose at your regularly scheduled time. </li> </ul> </li> <li class="valid" valid="valid" title="valid: True, node: 395, level: 11" node_number="395"> Reducing the risk of serious heart problems, heart attack and stroke in coronary artery&#160;disease or peripheral artery disease: <ul class="valid" valid="valid" title="valid: True, node: 396, level: 12" node_number="396"> <li class="valid" valid="valid" title="valid: True, node: 397, level: 13" node_number="397"> Take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 398, level: 14" node_number="398">&#174;</sup>&#160;2.5 mg 2&#160;times a day with or without food. </li> <li class="valid" valid="valid" title="valid: True, node: 399, level: 13" node_number="399"> If you miss a dose of XARELTO<sup class="valid" valid="valid" title="valid: True, node: 400, level: 14" node_number="400">&#174;</sup>, take your next dose at your regularly scheduled time. </li> <li class="valid" valid="valid" title="valid: True, node: 401, level: 13" node_number="401"> Take aspirin 75 to 100 mg once daily as instructed by your doctor. </li> </ul> </li> </ul> </ul> <div class="valid" valid="valid" title="valid: True, node: 402, level: 9" node_number="402"> <p class="valid" valid="valid" title="valid: True, node: 403, level: 10" node_number="403"> WHAT ARE THE POSSIBLE SIDE EFFECTS OF <span class="valid" valid="valid" title="valid: True, node: 404, level: 11" node_number="404">XARELTO<sup class="valid" valid="valid" title="valid: True, node: 405, level: 12" node_number="405">&#174;</sup>?</span> </p> <p class="valid" valid="valid" title="valid: True, node: 406, level: 10" node_number="406"> XARELTO<sup class="valid" valid="valid" title="valid: True, node: 407, level: 11" node_number="407">&#174;</sup> may cause serious side effects: </p> <ul class="valid" valid="valid" title="valid: True, node: 408, level: 10" node_number="408"> <li class="valid" valid="valid" title="valid: True, node: 409, level: 11" node_number="409"> See &#8220;What is the most important information I should know about XARELTO<sup class="valid" valid="valid" title="valid: True, node: 410, level: 12" node_number="410">&#174;</sup>?&#8221; </li> </ul> <p class="valid" valid="valid" title="valid: True, node: 411, level: 10" node_number="411"> The most common side effect of XARELTO<sup class="valid" valid="valid" title="valid: True, node: 412, level: 11" node_number="412">&#174;</sup> was bleeding. </p> <p class="valid" valid="valid" title="valid: True, node: 413, level: 10" node_number="413"> Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects to Janssen Pharmaceuticals, Inc., at 1-800-JANSSEN (1-800-526-7736). </p> <p class="valid" valid="valid" title="valid: True, node: 414, level: 10" node_number="414"> Please read full Prescribing Information, including Boxed Warnings, and Medication Guide for XARELTO<sup class="valid" valid="valid" title="valid: True, node: 415, level: 11" node_number="415">&#174;</sup>. </p> <p class="valid" valid="valid" title="valid: True, node: 416, level: 10" node_number="416"> Trademarks are those of their respective owners. </p> <p class="valid" valid="valid" title="valid: True, node: 417, level: 10" node_number="417"> cp-53637v6 </p> </div> </div> </div> </div> </div></div><div class="valid" valid="valid" title="valid: True, node: 418, level: 4" node_number="418"> <div class="valid" valid="valid" title="valid: True, node: 419, level: 5" node_number="419"> <p class="valid" valid="valid" title="valid: True, node: 420, level: 6" node_number="420">&#169; Janssen Pharmaceuticals, Inc. 2021May 2021cp-113688v4</p> </div> </div></div></div> <main class="valid" valid="valid" title="valid: True, node: 421, level: 2" node_number="421"> </main> <div class="valid" valid="valid" title="valid: True, node: 422, level: 2" node_number="422"><div class="valid" valid="valid" title="valid: True, node: 423, level: 3" node_number="423"><div class="valid" valid="valid" title="valid: True, node: 424, level: 4" node_number="424">WebMD does not endorse any specific product, service, or treatment.</div></div><div class="valid" valid="valid" title="valid: True, node: 425, level: 3" node_number="425"><div class="valid" valid="valid" title="valid: True, node: 426, level: 4" node_number="426"> <div class="valid" valid="valid" title="valid: True, node: 427, level: 5" node_number="427"> Show More </div> <div class="valid" valid="valid" title="valid: True, node: 428, level: 5" node_number="428"> <div class="valid" valid="valid" title="valid: True, node: 429, level: 6" node_number="429"><div class="valid" valid="valid" title="valid: True, node: 430, level: 7" node_number="430"> <div class="valid" valid="valid" title="valid: True, node: 431, level: 8" node_number="431"> <div class="valid" valid="valid" title="valid: True, node: 432, level: 9" node_number="432"> <div class="valid" valid="valid" title="valid: True, node: 433, level: 10" node_number="433"> <div class="valid" valid="valid" title="valid: True, node: 434, level: 11" node_number="434"> <div class="valid" valid="valid" title="valid: True, node: 435, level: 12" node_number="435"> WHAT IS XARELTO<sup class="valid" valid="valid" title="valid: True, node: 436, level: 13" node_number="436">&#174;</sup> (rivaroxaban)?</div> <div class="valid" valid="valid" title="valid: True, node: 437, level: 12" node_number="437"> <p class="valid" valid="valid" title="valid: True, node: 438, level: 13" node_number="438">XARELTO<sup class="valid" valid="valid" title="valid: True, node: 439, level: 14" node_number="439">&#174;</sup> is a prescription medicine used to:</p> <ul class="valid" valid="valid" title="valid: True, node: 440, level: 13" node_number="440"> <li class="valid" valid="valid" title="valid: True, node: 441, level: 14" node_number="441"> reduce the risk of stroke and blood clots in people who have a medical condition called atrial fibrillation that is not caused by a heart valve problem. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to the formation of blood clots, which can travel to the brain, causing a stroke, or to other parts of the body </li> <li class="valid" valid="valid" title="valid: True, node: 442, level: 14" node_number="442"> treat blood clots in the veins of your legs (deep vein thrombosis or DVT) or lungs (pulmonary embolism or PE) </li> <li class="valid" valid="valid" title="valid: True, node: 443, level: 14" node_number="443"> reduce the risk of blood clots happening again in people who continue to be at risk for DVT or PE after receiving treatment for blood clots for at least 6 months </li> </ul> <p class="valid" valid="valid" title="valid: True, node: 444, level: 13" node_number="444">XARELTO<sup class="valid" valid="valid" title="valid: True, node: 445, level: 14" node_number="445">&#174;</sup> is used with low dose aspirin to:</p> <ul class="valid" valid="valid" title="valid: True, node: 446, level: 13" node_number="446"> <li class="valid" valid="valid" title="valid: True, node: 447, level: 14" node_number="447"> reduce the risk of serious heart problems, heart attack and stroke in people with coronary artery disease (a condition where the blood supply to the heart is reduced or blocked) or peripheral artery disease (a condition where the blood flow to the legs is reduced) </li> </ul> <p class="valid" valid="valid" title="valid: True, node: 448, level: 13" node_number="448">It is not known if XARELTO<sup class="valid" valid="valid" title="valid: True, node: 449, level: 14" node_number="449">&#174;</sup> is safe and effective in children.</p> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 450, level: 11" node_number="450"> <div class="valid" valid="valid" title="valid: True, node: 451, level: 12" node_number="451">WHAT IS XARELTO<sup class="valid" valid="valid" title="valid: True, node: 452, level: 13" node_number="452">&#174;</sup> (rivaroxaban)?</div> <div class="valid" valid="valid" title="valid: True, node: 453, level: 12" node_number="453"> <p class="valid" valid="valid" title="valid: True, node: 454, level: 13" node_number="454">XARELTO<sup class="valid" valid="valid" title="valid: True, node: 455, level: 14" node_number="455">&#174;</sup> is a prescription medicine used to:</p> <ul class="valid" valid="valid" title="valid: True, node: 456, level: 13" node_number="456"> <li class="valid" valid="valid" title="valid: True, node: 457, level: 14" node_number="457">reduce the risk of stroke and blood clots in people who have a medical condition called atrial fibrillation that is not caused by a heart valve problem. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to the formation of blood clots, which can travel to the brain, causing a stroke, or to other parts of the body</li> </ul> <p class="valid" valid="valid" title="valid: True, node: 458, level: 13" node_number="458">It is not known if XARELTO<sup class="valid" valid="valid" title="valid: True, node: 459, level: 14" node_number="459">&#174;</sup> is safe and effective in children.</p> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 460, level: 11" node_number="460"> <div class="valid" valid="valid" title="valid: True, node: 461, level: 12" node_number="461">WHAT IS XARELTO<sup class="valid" valid="valid" title="valid: True, node: 462, level: 13" node_number="462">&#174;</sup> (rivaroxaban)?</div> <div class="valid" valid="valid" title="valid: True, node: 463, level: 12" node_number="463"> <p class="valid" valid="valid" title="valid: True, node: 464, level: 13" node_number="464">XARELTO<sup class="valid" valid="valid" title="valid: True, node: 465, level: 14" node_number="465">&#174;</sup> is a prescription medicine used to:</p> <ul class="valid" valid="valid" title="valid: True, node: 466, level: 13" node_number="466"> <li class="valid" valid="valid" title="valid: True, node: 467, level: 14" node_number="467">treat blood clots in the veins of your legs (deep vein thrombosis or DVT) or lungs (pulmonary embolism or PE)</li> <li class="valid" valid="valid" title="valid: True, node: 468, level: 14" node_number="468">reduce the risk of blood clots happening again in people who continue to be at risk for DVT or PE after receiving treatment for blood clots for at least 6 months</li> </ul> <p class="valid" valid="valid" title="valid: True, node: 469, level: 13" node_number="469">It is not known if XARELTO<sup class="valid" valid="valid" title="valid: True, node: 470, level: 14" node_number="470">&#174;</sup> is safe and effective in children.</p> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 471, level: 11" node_number="471"> <div class="valid" valid="valid" title="valid: True, node: 472, level: 12" node_number="472">WHAT IS XARELTO<sup class="valid" valid="valid" title="valid: True, node: 473, level: 13" node_number="473">&#174;</sup> (rivaroxaban)?</div> <div class="valid" valid="valid" title="valid: True, node: 474, level: 12" node_number="474"> <p class="valid" valid="valid" title="valid: True, node: 475, level: 13" node_number="475">XARELTO<sup class="valid" valid="valid" title="valid: True, node: 476, level: 14" node_number="476">&#174;</sup> is a prescription medicine used with low dose aspirin to:</p> <ul class="valid" valid="valid" title="valid: True, node: 477, level: 13" node_number="477"> <li class="valid" valid="valid" title="valid: True, node: 478, level: 14" node_number="478">reduce the risk of serious heart problems, heart attack and stroke in people with coronary artery disease (a condition where the blood supply to the heart is reduced or blocked) or peripheral artery disease (a condition where the blood flow to the legs is reduced) </li> </ul> <p class="valid" valid="valid" title="valid: True, node: 479, level: 13" node_number="479">It is not known if XARELTO<sup class="valid" valid="valid" title="valid: True, node: 480, level: 14" node_number="480">&#174;</sup> is safe and effective in children.</p> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 481, level: 10" node_number="481"> <h3 class="valid" valid="valid" title="valid: True, node: 482, level: 11" node_number="482">IMPORTANT SAFETY INFORMATION</h3> <p class="valid" valid="valid" title="valid: True, node: 483, level: 11" node_number="483">WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT XARELTO<sup class="valid" valid="valid" title="valid: True, node: 484, level: 12" node_number="484">&#174;</sup>?</p> <p class="valid" valid="valid" title="valid: True, node: 485, level: 11" node_number="485"> XARELTO<sup class="valid" valid="valid" title="valid: True, node: 486, level: 12" node_number="486">&#174;</sup> may cause serious side effects, including: </p> <ul class="valid" valid="valid" title="valid: True, node: 487, level: 11" node_number="487"> <li class="valid" valid="valid" title="valid: True, node: 488, level: 12" node_number="488"> Increased risk of blood clots if you stop taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 489, level: 13" node_number="489">&#174;</sup>. People with atrial fibrillation (an irregular heart beat) that is not caused by a heart valve problem (nonvalvular) are at an increased risk of forming a blood clot in the heart, which can travel to the brain, causing a stroke, or to other parts of the body. XARELTO<sup class="valid" valid="valid" title="valid: True, node: 490, level: 13" node_number="490">&#174;</sup> lowers your chance of having a stroke by helping to prevent clots from forming. If you stop taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 491, level: 13" node_number="491">&#174;</sup>, you may have increased risk of forming a clot in your blood. </li> <li class="valid" valid="valid" title="valid: True, node: 492, level: 12" node_number="492"> Do not stop taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 493, level: 13" node_number="493">&#174;</sup> without talking to the doctor who prescribes it for you. Stopping XARELTO<sup class="valid" valid="valid" title="valid: True, node: 494, level: 13" node_number="494">&#174;</sup> increases your risk of having a stroke. If you have to stop taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 495, level: 13" node_number="495">&#174;</sup>, your doctor may prescribe another blood thinner medicine to prevent a blood clot from forming. </li> <li class="valid" valid="valid" title="valid: True, node: 496, level: 12" node_number="496"> Increased risk of bleeding. XARELTO<sup class="valid" valid="valid" title="valid: True, node: 497, level: 13" node_number="497">&#174;</sup> can cause bleeding which can be serious, and may lead to death. This is because XARELTO<sup class="valid" valid="valid" title="valid: True, node: 498, level: 13" node_number="498">&#174;</sup> is a blood thinner medicine (anticoagulant) that lowers blood clotting. During treatment with XARELTO<sup class="valid" valid="valid" title="valid: True, node: 499, level: 13" node_number="499">&#174;</sup> you are likely to bruise more easily, and it may take longer for bleeding to stop. You may be at higher risk of bleeding if you take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 500, level: 13" node_number="500">&#174;</sup> and have certain other medical problems. </li> </ul> <p class="valid" valid="valid" title="valid: True, node: 501, level: 11" node_number="501"> You may have a higher risk of bleeding if you take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 502, level: 12" node_number="502">&#174;</sup> and take other medicines that increase your risk of bleeding, including: </p> <ul class="valid" valid="valid" title="valid: True, node: 503, level: 11" node_number="503"> <li class="valid" valid="valid" title="valid: True, node: 504, level: 12" node_number="504">Aspirin or aspirin-containing products</li> <li class="valid" valid="valid" title="valid: True, node: 505, level: 12" node_number="505">Long-term (chronic) use of non-steroidal anti-inflammatory drugs (NSAIDs)</li> <li class="valid" valid="valid" title="valid: True, node: 506, level: 12" node_number="506">Warfarin sodium (Coumadin<sup class="valid" valid="valid" title="valid: True, node: 507, level: 13" node_number="507">&#174;</sup>, Jantoven<sup class="valid" valid="valid" title="valid: True, node: 508, level: 13" node_number="508">&#174;</sup>)</li> <li class="valid" valid="valid" title="valid: True, node: 509, level: 12" node_number="509">Any medicine that contains heparin</li> <li class="valid" valid="valid" title="valid: True, node: 510, level: 12" node_number="510">Clopidogrel (Plavix<sup class="valid" valid="valid" title="valid: True, node: 511, level: 13" node_number="511">&#174;</sup>)</li> <li class="valid" valid="valid" title="valid: True, node: 512, level: 12" node_number="512">Selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs)</li> <li class="valid" valid="valid" title="valid: True, node: 513, level: 12" node_number="513">Other medicines to prevent or treat blood clots</li> </ul> <p class="valid" valid="valid" title="valid: True, node: 514, level: 11" node_number="514"> Tell your doctor if you take any of these medicines. Ask your doctor or pharmacist if you are not sure if your medicine is one listed above. </p> <p class="valid" valid="valid" title="valid: True, node: 515, level: 11" node_number="515"> Call your doctor or get medical help right away if you develop any of these signs or symptoms of bleeding: </p> <ul class="valid" valid="valid" title="valid: True, node: 516, level: 11" node_number="516"> <li class="valid" valid="valid" title="valid: True, node: 517, level: 12" node_number="517">Unexpected bleeding or bleeding that lasts a long time, such as:</li> </ul> <ul class="valid" valid="valid" title="valid: True, node: 518, level: 11" node_number="518"> <li class="valid" valid="valid" title="valid: True, node: 519, level: 12" node_number="519">Nosebleeds that happen often</li> <li class="valid" valid="valid" title="valid: True, node: 520, level: 12" node_number="520">Unusual bleeding from gums</li> <li class="valid" valid="valid" title="valid: True, node: 521, level: 12" node_number="521">Menstrual bleeding that is heavier than normal, or vaginal bleeding</li> </ul> <ul class="valid" valid="valid" title="valid: True, node: 522, level: 11" node_number="522"> <li class="valid" valid="valid" title="valid: True, node: 523, level: 12" node_number="523">Bleeding that is severe or you cannot control</li> <li class="valid" valid="valid" title="valid: True, node: 524, level: 12" node_number="524">Red, pink, or brown urine</li> <li class="valid" valid="valid" title="valid: True, node: 525, level: 12" node_number="525">Bright red or black stools (looks like tar)</li> <li class="valid" valid="valid" title="valid: True, node: 526, level: 12" node_number="526">Cough up blood or blood clots</li> <li class="valid" valid="valid" title="valid: True, node: 527, level: 12" node_number="527">Vomit blood or your vomit looks like "coffee grounds"</li> <li class="valid" valid="valid" title="valid: True, node: 528, level: 12" node_number="528">Headaches, feeling dizzy or weak</li> <li class="valid" valid="valid" title="valid: True, node: 529, level: 12" node_number="529">Pain, swelling, or new drainage at wound sites</li> </ul> <li class="valid" valid="valid" title="valid: True, node: 530, level: 11" node_number="530"> Spinal or epidural blood clots (hematoma).&#160;People who take a blood thinner medicine (anticoagulant) like XARELTO<sup class="valid" valid="valid" title="valid: True, node: 531, level: 12" node_number="531">&#174;</sup>, and have medicine injected into their spinal and epidural area, or have a spinal puncture, have a risk of forming a blood clot that can cause long-term or permanent loss of the ability to move (paralysis). Your risk of developing a spinal or epidural blood clot is higher if: <ul class="valid" valid="valid" title="valid: True, node: 532, level: 12" node_number="532"> <li class="valid" valid="valid" title="valid: True, node: 533, level: 13" node_number="533"> A thin tube called an epidural catheter is placed in your back to give you certain medicine </li> <li class="valid" valid="valid" title="valid: True, node: 534, level: 13" node_number="534"> You take NSAIDs or a medicine to prevent blood from clotting </li> <li class="valid" valid="valid" title="valid: True, node: 535, level: 13" node_number="535"> You have a history of difficult or repeated epidural or spinal punctures </li> <li class="valid" valid="valid" title="valid: True, node: 536, level: 13" node_number="536"> You have a history of problems with your spine or have had surgery on your spine </li> </ul> </li> <p class="valid" valid="valid" title="valid: True, node: 537, level: 11" node_number="537"> If you take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 538, level: 12" node_number="538">&#174;</sup> and receive spinal anesthesia or have a spinal puncture, your doctor should watch you closely for symptoms of spinal or epidural blood clots. Tell your doctor right away if you have back pain, tingling, numbness, muscle weakness (especially in your legs and feet), or loss of control of the bowels or bladder (incontinence). </p> <p class="valid" valid="valid" title="valid: True, node: 539, level: 11" node_number="539"> XARELTO<sup class="valid" valid="valid" title="valid: True, node: 540, level: 12" node_number="540">&#174;</sup> is not for use in people with artificial heart valves. </p> <p class="valid" valid="valid" title="valid: True, node: 541, level: 11" node_number="541"> XARELTO<sup class="valid" valid="valid" title="valid: True, node: 542, level: 12" node_number="542">&#174;</sup> is not for use in people with antiphospholipid syndrome (APS), especially with positive triple antibody testing. </p> <p class="valid" valid="valid" title="valid: True, node: 543, level: 11" node_number="543"> &#8203;&#8203;Do not take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 544, level: 12" node_number="544">&#174;</sup> if you: </p> <ul class="valid" valid="valid" title="valid: True, node: 545, level: 11" node_number="545"> <li class="valid" valid="valid" title="valid: True, node: 546, level: 12" node_number="546"> Currently have certain types of abnormal bleeding. Talk to your doctor before taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 547, level: 13" node_number="547">&#174;</sup> if you currently have unusual bleeding. </li> <li class="valid" valid="valid" title="valid: True, node: 548, level: 12" node_number="548"> Are allergic to rivaroxaban or any of the ingredients of XARELTO<sup class="valid" valid="valid" title="valid: True, node: 549, level: 13" node_number="549">&#174;</sup>. </li> </ul> <p class="valid" valid="valid" title="valid: True, node: 550, level: 11" node_number="550"> &#8203;&#8203;Before taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 551, level: 12" node_number="551">&#174;</sup>, tell your doctor about all your medical conditions, including if you: </p> <ul class="valid" valid="valid" title="valid: True, node: 552, level: 11" node_number="552"> <li class="valid" valid="valid" title="valid: True, node: 553, level: 12" node_number="553"> Have ever had bleeding problems </li> <li class="valid" valid="valid" title="valid: True, node: 554, level: 12" node_number="554"> Have liver or kidney problems </li> <li class="valid" valid="valid" title="valid: True, node: 555, level: 12" node_number="555"> Have antiphospholipid syndrome (APS) </li> <li class="valid" valid="valid" title="valid: True, node: 556, level: 12" node_number="556"> Are pregnant or plan to become pregnant. It is not known if XARELTO<sup class="valid" valid="valid" title="valid: True, node: 557, level: 13" node_number="557">&#174;</sup> will harm your unborn baby. <ul class="valid" valid="valid" title="valid: True, node: 558, level: 13" node_number="558"> <li class="valid" valid="valid" title="valid: True, node: 559, level: 14" node_number="559"> Tell your doctor right away if you become pregnant during treatment with XARELTO<sup title="valid: False, node: 560, level: 15" node_number="560">&#174;</sup>. Taking XARELTO<sup title="valid: False, node: 561, level: 15" node_number="561">&#174;</sup> while you are pregnant may increase the risk of bleeding in you or in your unborn baby. </li> <li class="valid" valid="valid" title="valid: True, node: 562, level: 14" node_number="562"> If you take XARELTO<sup title="valid: False, node: 563, level: 15" node_number="563">&#174;</sup> during pregnancy, tell your doctor right away if you have any signs or symptoms of bleeding or blood loss.&#160;See &#8220;What is the most important information I should know about XARELTO<sup title="valid: False, node: 564, level: 15" node_number="564">&#174;</sup>?&#8221; for signs and symptoms of bleeding. </li> </ul> </li> <li class="valid" valid="valid" title="valid: True, node: 565, level: 12" node_number="565"> Are breastfeeding or plan to breastfeed. XARELTO<sup class="valid" valid="valid" title="valid: True, node: 566, level: 13" node_number="566">&#174;</sup> may pass into your breast milk. Talk to your doctor about the best way to feed your baby during treatment with XARELTO<sup class="valid" valid="valid" title="valid: True, node: 567, level: 13" node_number="567">&#174;</sup>. </li> </ul> <p class="valid" valid="valid" title="valid: True, node: 568, level: 11" node_number="568"> Tell all of your doctors and dentists that you are taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 569, level: 12" node_number="569">&#174;</sup>. They should talk to the doctor who prescribed XARELTO<sup class="valid" valid="valid" title="valid: True, node: 570, level: 12" node_number="570">&#174;</sup> for you before you have any surgery, medical or dental procedure. </p> <p class="valid" valid="valid" title="valid: True, node: 571, level: 11" node_number="571"> Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements<b class="valid" valid="valid" title="valid: True, node: 572, level: 12" node_number="572">. </b> </p> <p class="valid" valid="valid" title="valid: True, node: 573, level: 11" node_number="573"> Some of your other medicines may affect the way XARELTO<sup class="valid" valid="valid" title="valid: True, node: 574, level: 12" node_number="574">&#174;</sup> works, causing side effects. Certain medicines may increase your risk of bleeding. See &#8220;What is the most important information I should know about XARELTO<sup class="valid" valid="valid" title="valid: True, node: 575, level: 12" node_number="575">&#174;</sup>?&#8221; </p> <p class="valid" valid="valid" title="valid: True, node: 576, level: 11" node_number="576"> HOW SHOULD I TAKE XARELTO<sup class="valid" valid="valid" title="valid: True, node: 577, level: 12" node_number="577">&#174;</sup>? </p> <ul class="valid" valid="valid" title="valid: True, node: 578, level: 11" node_number="578"> <li class="valid" valid="valid" title="valid: True, node: 579, level: 12" node_number="579"> Take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 580, level: 13" node_number="580">&#174;</sup> exactly as prescribed by your doctor. </li> <li class="valid" valid="valid" title="valid: True, node: 581, level: 12" node_number="581"> Do not change your dose or stop taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 582, level: 13" node_number="582">&#174;</sup> unless your doctor tells you to. Your doctor may change your dose if needed. </li> <li class="valid" valid="valid" title="valid: True, node: 583, level: 12" node_number="583"> Your doctor will decide how long you should take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 584, level: 13" node_number="584">&#174;</sup>. </li> <li class="valid" valid="valid" title="valid: True, node: 585, level: 12" node_number="585"> XARELTO<sup class="valid" valid="valid" title="valid: True, node: 586, level: 13" node_number="586">&#174;</sup> may need to be stopped for one or more days before any surgery or medical or dental procedure. Your doctor will tell you when to stop taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 587, level: 13" node_number="587">&#174;</sup> and when to start taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 588, level: 13" node_number="588">&#174;</sup> again after your surgery or procedure. </li> <li class="valid" valid="valid" title="valid: True, node: 589, level: 12" node_number="589"> If you need to stop taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 590, level: 13" node_number="590">&#174;</sup> for any reason, talk to the doctor who prescribed XARELTO<sup class="valid" valid="valid" title="valid: True, node: 591, level: 13" node_number="591">&#174;</sup> to you to find out when you should stop taking it. Do not stop taking XARELTO<sup class="valid" valid="valid" title="valid: True, node: 592, level: 13" node_number="592">&#174;</sup> without first talking to the doctor who prescribes it to you. </li> <li class="valid" valid="valid" title="valid: True, node: 593, level: 12" node_number="593"> If you have difficulty swallowing XARELTO<sup class="valid" valid="valid" title="valid: True, node: 594, level: 13" node_number="594">&#174;</sup> tablets whole, talk to your doctor about other ways to take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 595, level: 13" node_number="595">&#174;</sup>. </li> <li class="valid" valid="valid" title="valid: True, node: 596, level: 12" node_number="596"> Do not run out of XARELTO<sup class="valid" valid="valid" title="valid: True, node: 597, level: 13" node_number="597">&#174;</sup>. Refill your prescription of XARELTO<sup class="valid" valid="valid" title="valid: True, node: 598, level: 13" node_number="598">&#174;</sup> before you run out. When leaving the hospital following a hip or knee replacement, be sure that you will have XARELTO<sup class="valid" valid="valid" title="valid: True, node: 599, level: 13" node_number="599">&#174;</sup> available to avoid missing any doses. </li> <li class="valid" valid="valid" title="valid: True, node: 600, level: 12" node_number="600"> If you take too much XARELTO<sup class="valid" valid="valid" title="valid: True, node: 601, level: 13" node_number="601">&#174;</sup>, go to the nearest hospital emergency room or call your doctor right away. </li> </ul> <p class="valid" valid="valid" title="valid: True, node: 602, level: 11" node_number="602"> If you take XARELTO<sup class="valid" valid="valid" title="valid: True, node: 603, level: 12" node_number="603">&#174;</sup> for:&#8203; </p> <ul class="valid" valid="valid" title="valid: True, node: 604, level: 11" node_number="604"> <ul class="valid" valid="valid" title="valid: True, node: 605, level: 12" node_number="605"> <li class="valid" valid="valid" title="valid: True, node: 606, level: 13" node_number="606"> Atrial Fibrillation that is not caused by a heart valve problem: <ul class="valid" valid="valid" title="valid: True, node: 607, level: 14" node_number="607"> <li title="valid: False, node: 608, level: 15" node_number="608"> Take XARELTO<sup title="valid: False, node: 609, level: 16" node_number="609">&#174;</sup> 1 time a day with your evening meal. </li> <li title="valid: False, node: 610, level: 15" node_number="610"> If you miss a dose of XARELTO<sup title="valid: False, node: 611, level: 16" node_number="611">&#174;</sup>, take it as soon as you remember on the same day.&#160;Take your next dose at your regularly scheduled time. </li> </ul> </li> <li class="valid" valid="valid" title="valid: True, node: 612, level: 13" node_number="612"> Blood clots in the veins of your legs or lungs: <ul class="valid" valid="valid" title="valid: True, node: 613, level: 14" node_number="613"> <li title="valid: False, node: 614, level: 15" node_number="614"> Take XARELTO<sup title="valid: False, node: 615, level: 16" node_number="615">&#174;&#160;</sup>1 or 2 times a day as prescribed by your doctor. </li> <li title="valid: False, node: 616, level: 15" node_number="616"> For the 10-mg dose, XARELTO<sup title="valid: False, node: 617, level: 16" node_number="617">&#174;</sup> may be taken with or without food. </li> <li title="valid: False, node: 618, level: 15" node_number="618"> For the 15-mg and 20-mg doses, take XARELTO<sup title="valid: False, node: 619, level: 16" node_number="619">&#174;</sup> with food at the same time each day. </li> <li title="valid: False, node: 620, level: 15" node_number="620"> If you miss a dose: <ul title="valid: False, node: 621, level: 16" node_number="621"> <li title="valid: False, node: 622, level: 17" node_number="622"> If you take the 15-mg dose of XARELTO<sup title="valid: False, node: 623, level: 18" node_number="623">&#174;</sup> 2 times a day (a total of 30 mg of XARELTO<sup title="valid: False, node: 624, level: 18" node_number="624">&#174;</sup> in 1 day):&#160;Take XARELTO<sup title="valid: False, node: 625, level: 18" node_number="625">&#174;</sup> as soon as you remember on the same day. You may take 2 doses at the same time to make up for the missed dose. Take your next dose at your regularly scheduled time. </li> <li title="valid: False, node: 626, level: 17" node_number="626"> If you take XARELTO<sup title="valid: False, node: 627, level: 18" node_number="627">&#174;</sup> 1 time a day: Take XARELTO<sup title="valid: False, node: 628, level: 18" node_number="628">&#174;</sup> as soon as you remember on the same day. Take your next dose at your regularly scheduled time.&#8203; </li> </ul> </li> </ul> </li> <li class="valid" valid="valid" title="valid: True, node: 629, level: 13" node_number="629"> Hip or knee replacement surgery: <ul class="valid" valid="valid" title="valid: True, node: 630, level: 14" node_number="630"> <li title="valid: False, node: 631, level: 15" node_number="631"> Take XARELTO<sup title="valid: False, node: 632, level: 16" node_number="632">&#174;</sup> 1 time a day with or without food. </li> <li title="valid: False, node: 633, level: 15" node_number="633"> If you miss a dose of XARELTO<sup title="valid: False, node: 634, level: 16" node_number="634">&#174;</sup>, take it as soon as you remember on the same day. Take your next dose at your regularly scheduled time. </li> </ul> </li> <li class="valid" valid="valid" title="valid: True, node: 635, level: 13" node_number="635"> Blood clots in people hospitalized for an acute illness: <ul class="valid" valid="valid" title="valid: True, node: 636, level: 14" node_number="636"> <li title="valid: False, node: 637, level: 15" node_number="637"> Take XARELTO<sup title="valid: False, node: 638, level: 16" node_number="638">&#174;</sup>&#160;1&#160;time a day, with or without food, while you are in the hospital and after you are discharged as prescribed by your doctor. </li> <li title="valid: False, node: 639, level: 15" node_number="639"> If you miss a dose of XARELTO<sup title="valid: False, node: 640, level: 16" node_number="640">&#174;</sup>, take it as soon as you remember on the same day. Take your next dose at your regularly scheduled time. </li> </ul> </li> <li class="valid" valid="valid" title="valid: True, node: 641, level: 13" node_number="641"> Reducing the risk of serious heart problems, heart attack and stroke in coronary artery&#160;disease or peripheral artery disease: <ul class="valid" valid="valid" title="valid: True, node: 642, level: 14" node_number="642"> <li title="valid: False, node: 643, level: 15" node_number="643"> Take XARELTO<sup title="valid: False, node: 644, level: 16" node_number="644">&#174;</sup>&#160;2.5 mg 2&#160;times a day with or without food. </li> <li title="valid: False, node: 645, level: 15" node_number="645"> If you miss a dose of XARELTO<sup title="valid: False, node: 646, level: 16" node_number="646">&#174;</sup>, take your next dose at your regularly scheduled time. </li> <li title="valid: False, node: 647, level: 15" node_number="647"> Take aspirin 75 to 100 mg once daily as instructed by your doctor. </li> </ul> </li> </ul> </ul> <div class="valid" valid="valid" title="valid: True, node: 648, level: 11" node_number="648"> <p class="valid" valid="valid" title="valid: True, node: 649, level: 12" node_number="649"> WHAT ARE THE POSSIBLE SIDE EFFECTS OF <span class="valid" valid="valid" title="valid: True, node: 650, level: 13" node_number="650">XARELTO<sup class="valid" valid="valid" title="valid: True, node: 651, level: 14" node_number="651">&#174;</sup>?</span> </p> <p class="valid" valid="valid" title="valid: True, node: 652, level: 12" node_number="652"> XARELTO<sup class="valid" valid="valid" title="valid: True, node: 653, level: 13" node_number="653">&#174;</sup> may cause serious side effects: </p> <ul class="valid" valid="valid" title="valid: True, node: 654, level: 12" node_number="654"> <li class="valid" valid="valid" title="valid: True, node: 655, level: 13" node_number="655"> See &#8220;What is the most important information I should know about XARELTO<sup class="valid" valid="valid" title="valid: True, node: 656, level: 14" node_number="656">&#174;</sup>?&#8221; </li> </ul> <p class="valid" valid="valid" title="valid: True, node: 657, level: 12" node_number="657"> The most common side effect of XARELTO<sup class="valid" valid="valid" title="valid: True, node: 658, level: 13" node_number="658">&#174;</sup> was bleeding. </p> <p class="valid" valid="valid" title="valid: True, node: 659, level: 12" node_number="659"> Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects to Janssen Pharmaceuticals, Inc., at 1-800-JANSSEN (1-800-526-7736). </p> <p class="valid" valid="valid" title="valid: True, node: 660, level: 12" node_number="660"> Please read full <a class="valid" valid="valid" title="valid: True, node: 661, level: 13" node_number="661">Prescribing Information</a>, including Boxed Warnings, and <a class="valid" valid="valid" title="valid: True, node: 662, level: 13" node_number="662">Medication Guide</a> for XARELTO<sup class="valid" valid="valid" title="valid: True, node: 663, level: 13" node_number="663">&#174;</sup>. </p> <p class="valid" valid="valid" title="valid: True, node: 664, level: 12" node_number="664"> Trademarks are those of their respective owners. </p> <p class="valid" valid="valid" title="valid: True, node: 665, level: 12" node_number="665"> cp-53637v6 </p> </div> </div> </div> </div> </div></div> </div> </div> </div></div> </body>
        <style tyle='text/css'>
body{
    position: relative;
    padding-left: 30px;
    top: 60px;
}
* {
    border: 1px solid #eee;
    padding: 5px 12px;
    margin: 3px 0;
    box-sizing: content-box;
    background-color: #fff;
    cursor: no-drop;
}
main:hover > *, section:hover > *, header:hover > *, nav:hover > *, a:hover > *, div:hover > *, p:hover > *, ul:hover > *, h1:hover > *, h2:hover > *, h3:hover > *, li:hover > *, span:hover > *{
    border: 2px solid green;
    background-color: #fffeee;
    padding: 5px 23px !important;
    margin: 1px 0;
    color: green;
}
main:hover, section:hover, header:hover, nav:hover, a:hover, div:hover, p:hover, ul:hover, h1:hover, h2:hover, h3:hover, li:hover, span:hover{
    border: 1px solid #fff;
    background-color: #eee;
}
a, span {
    display: block;
}
.selected {
    border: 2px solid orchid !important;
    opacity: 0.8;
    color: orchid !important;
}
.selected * {
    padding: 2px !important;
    color: orchid !important;
}
.valid {
  cursor: pointer;
}
.btn{
  cursor: pointer;
  font-weight: bolder;
  padding: 8px;
}
</style> 
        <script>function OpenOriginalLink($event){
    $event.stopPropagation();
    console.log(url);
}

function removeItem($event){
    $event.stopPropagation();
    console.log('Remove item: ', url)
    localStorage.removeItem(url)
}

function exportData($event){
    $event.stopPropagation();

    result = []
    for(let i=0; i<localStorage.length; i++) {
        let key = localStorage.key(i);
        result.push(localStorage.getItem(key))
    }
    const _url = URL.createObjectURL(new Blob([result.join("\n")], {type: 'text/plain'}))
    $event.target.href = _url;
    localStorage.clear()
}

var removeItemBtn = document.createElement("BUTTON");   // Create a <button> element
removeItemBtn.innerHTML = "Remove Item";
removeItemBtn.classList.add('btn');
removeItemBtn.style.position = "fixed";
removeItemBtn.style.left = '5px';
removeItemBtn.style.top = 0;
removeItemBtn.style.border = "1px solid";
removeItemBtn.style.boxShadow = "3px 3px #888";
removeItemBtn.onclick = removeItem;
document.body.appendChild(removeItemBtn);

var goToOriginLink = document.createElement("A");   // Create a <button> element
goToOriginLink.innerHTML = "GoToOrigin";
goToOriginLink.classList.add('btn');
goToOriginLink.style.position = "fixed"
goToOriginLink.style.left = '115px'
goToOriginLink.style.top = 0;
goToOriginLink.onclick = OpenOriginalLink;
goToOriginLink.setAttribute('href', decodeURIComponent(url));
goToOriginLink.target = '_blank';
document.body.appendChild(goToOriginLink);

var current = new Date
var exportDataLink = document.createElement("A");   // Create a <button> element
exportDataLink.innerHTML = "Export data";
exportDataLink.classList.add('btn');
exportDataLink.download = current.toISOString() + '.exported.txt';
exportDataLink.style.position = "fixed";
exportDataLink.style.right = '5px';
exportDataLink.style.top = 0;
exportDataLink.style.border = "1px solid #888";
exportDataLink.style.boxShadow = "3px 3px #888";
exportDataLink.onclick = exportData;
document.body.appendChild(exportDataLink);

data = {
    'title': null ,
    'article': null
}

var body = document.getElementsByTagName("body")[0];

body.onclick = function($e){
    var num = $e.target.getAttribute('node_number')
    var valid = $e.target.getAttribute('valid')

    if(!valid){
        console.log("Element is invalid")
        return
    }

    if(data.length > 2){
        data = data.splice(0, 2)
    }

    console.log("node:", $e.target)

    if(!data.title && !data.article){
        data.title = num;
        console.log("data:", data)
        $e.target.classList.add('selected')
    }else if (data.title && !data.article){
        data.article = num;
        console.log("data:", data)
        $e.target.classList.add('selected')
    }else{
        selected = Array.from(document.getElementsByClassName("selected"))
        selected.forEach(function(el){
            el.classList.remove('selected')
        })

        data.title = num;
        data.article = null;
        $e.target.classList.add('selected')

    }

    if(data.title && data.article){
        var obj = {
            url: url,
            text: body_html,
            title: data.title,
            article: data.article,
        }

        var datasetItem = JSON.stringify(obj)
        localStorage.setItem(url, datasetItem)
    }
}
</script> 
      </html>